var title_f42_35_43568="Discolored amniotic fluid";
var content_f42_35_43568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Samples of amniotic fluid taken during genetic amniocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal amniotic fluid (left) is clear bright yellow. Dark green or brown amniotic fluid (right) indicates blood degradation products caused by prior bleeding. latter sample was obtained from patient in figure 3. Level of alpha-fetoprotein in amniotic fluid may be elevated as a result of bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trop, I, Levine, D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright 2001 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43568=[""].join("\n");
var outline_f42_35_43568=null;
var title_f42_35_43569="Intersection syndrome location";
var content_f42_35_43569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intersection syndrome location",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intersection syndrome affects the dorsum of the forearm a few centimeters proximal to the wrist joint at the intersection of the muscle bellies of the abductor pollicis longus and extensor pollicis brevis, where they cross over the extensor carpi radialis longus and the extensor carpi radialis brevis tendons.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43569=[""].join("\n");
var outline_f42_35_43569=null;
var title_f42_35_43570="Hydroxypropyl methylcellulose: Drug information";
var content_f42_35_43570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxypropyl methylcellulose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/15/31987?source=see_link\">",
"    see \"Hydroxypropyl methylcellulose: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cellugel&reg;;",
"     </li>",
"     <li>",
"      GenTeal&reg; Mild [OTC];",
"     </li>",
"     <li>",
"      GenTeal&reg; [OTC];",
"     </li>",
"     <li>",
"      Gonak&trade;;",
"     </li>",
"     <li>",
"      Goniosoft&trade; [OTC];",
"     </li>",
"     <li>",
"      Isopto&reg; Tears [OTC];",
"     </li>",
"     <li>",
"      Natural Balance Tears [OTC];",
"     </li>",
"     <li>",
"      Nature's Tears [OTC];",
"     </li>",
"     <li>",
"      Tears Again&reg; MC Gel Drops&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Genteal&reg;;",
"     </li>",
"     <li>",
"      Isopto&reg; Tears",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent, Ophthalmic;",
"     </li>",
"     <li>",
"      Lubricant, Ocular",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dry eyes: Ophthalmic: Instill 1-2 drops in affected eye(s) as needed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, ophthalmic [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GenTeal&reg;: 0.3% (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cellugel&reg;: 2% (1 mL) [contains natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gonak&trade;: 2.5% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Goniosoft&trade;: 2.5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Tears: 0.5% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natural Balance Tears: 0.4% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nature's Tears: 0.4% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tears Again&reg; MC Gel Drops&trade;: 0.3% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GenTeal&reg;: 0.3% (15 mL, 25 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GenTeal&reg; Mild: 0.2% (15 mL, 25 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of burning and minor irritation due to dry eyes; diagnostic agent in gonioscopic examination",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F180979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Isopto&reg; Tears may be confused with Isoptin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxypropyl methylcellulose or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Remove contact lenses prior to use. Not labeled for OTC use for &gt;72 hours. Do not use if solution changes color or becomes cloudy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Systane Overnight Therapy Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (10 g): $10.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cellugel Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (1 mL): $101.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (GenTeal Mild Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (15 mL): $8.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gonak Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (15 mL): $11.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Goniosol Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (15 mL): $18.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isopto Tears Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $27.60",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F180948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Artelac (AE, AT, BE, BG, BH, CY, DK, EG, FI, FR, GB, HU, IE, IL, IQ, IR, JO, KW, LB, LU, LY, OM, PH, PL, QA, SA, SE, SY, TW, YE);",
"     </li>",
"     <li>",
"      Artific (ES);",
"     </li>",
"     <li>",
"      Bion Tears (AU);",
"     </li>",
"     <li>",
"      Celulose Grin (MX);",
"     </li>",
"     <li>",
"      Genteal (AR, CO, EC, ID, IL, IN, KP, SG, TH);",
"     </li>",
"     <li>",
"      Humalac B (HU);",
"     </li>",
"     <li>",
"      Hydromoor (GB, IE);",
"     </li>",
"     <li>",
"      Hypromellose (NL);",
"     </li>",
"     <li>",
"      Ilube (PH);",
"     </li>",
"     <li>",
"      Isopto Plain (AE, BH, CY, EG, GB, IE, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Isopto Tears (AU, BF, BJ, CH, CI, ET, GH, GM, GN, HR, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, PL, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lac-Oph (HK);",
"     </li>",
"     <li>",
"      Lacrisic (DE);",
"     </li>",
"     <li>",
"      Lacrisifi (PE);",
"     </li>",
"     <li>",
"      Lacrystat (LU);",
"     </li>",
"     <li>",
"      Lagrimas Artificiales (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Methocel (PL, SG, TW);",
"     </li>",
"     <li>",
"      Methopt Eye Drops (AU, NZ, PH, TW);",
"     </li>",
"     <li>",
"      Meticel (CR, DO, PA);",
"     </li>",
"     <li>",
"      Metilcellulosa (IT);",
"     </li>",
"     <li>",
"      Min Young (TW);",
"     </li>",
"     <li>",
"      Naturalag (MX);",
"     </li>",
"     <li>",
"      Occucoat (LU);",
"     </li>",
"     <li>",
"      Ocucoat (KP);",
"     </li>",
"     <li>",
"      Ocucort (KP);",
"     </li>",
"     <li>",
"      Opsil Tears (TH);",
"     </li>",
"     <li>",
"      Optal Tears (TH);",
"     </li>",
"     <li>",
"      OQ-Coat (CO);",
"     </li>",
"     <li>",
"      Poly-Tears Eye Drops (NZ);",
"     </li>",
"     <li>",
"      Tears Natural II (IL);",
"     </li>",
"     <li>",
"      Tears Naturale (KP, NZ, PL);",
"     </li>",
"     <li>",
"      Ultra Tears (CH)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8979 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43570=[""].join("\n");
var outline_f42_35_43570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180950\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180951\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180975\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180953\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180954\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180944\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180935\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180945\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180979\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180947\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180938\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299493\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220910\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323188\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180948\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8979|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/15/31987?source=related_link\">",
"      Hydroxypropyl methylcellulose: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_35_43571="Hemihyperplasia in a patient with Beckwith-Wiedemann syndrome";
var content_f42_35_43571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Hemihyperplasia in a patient with Beckwith-Wiedemann syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43571=[""].join("\n");
var outline_f42_35_43571=null;
var title_f42_35_43572="Pralatrexate: Patient drug information";
var content_f42_35_43572=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pralatrexate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/43/29366?source=see_link\">",
"     see \"Pralatrexate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9407902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Folotyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692073",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer from lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705234",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pralatrexate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nosebleed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698326",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give you a vitamin B",
"       <sub>",
"        12",
"       </sub>",
"       shot 10 days before and every 8 to 10 weeks during your care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697826",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take folic acid within 10 days before, during, and for 30 days after your care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12296 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-89.32.226.102-AFF8269390-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43572=[""].join("\n");
var outline_f42_35_43572=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9407902\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028016\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028018\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028017\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028022\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028023\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028025\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028020\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028027\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/43/29366?source=related_link\">",
"      Pralatrexate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_35_43573="ECG Mobitz type I AV block";
var content_f42_35_43573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing Mobitz type I (Wenckebach) Atrioventricular (AV) block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 151px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single lead electrocardiogram (ECG) showing Mobitz type I (Wenckebach) second degree AV block with 5:4 conduction. The characteristics of this arrhythmia include: a progressively increasing PR interval until a P wave is not conducted (arrow); a progressive decrease in the increment in the PR interval; a progressive decrease in the RR interval; and the RR interval that includes the dropped beat (0.96 sec) is less than twice the RR interval between conducted beats (0.53 to 0.57 sec).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43573=[""].join("\n");
var outline_f42_35_43573=null;
var title_f42_35_43574="Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Drug information";
var content_f42_35_43574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/49/17169?source=see_link\">",
"    see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/51/29493?source=see_link\">",
"    see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3000502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gardasil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5994263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gardasil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3000506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3000566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Immunization regimen:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     I.M.: Children &ge;9 years and Adults &le;26 years: 0.5 mL followed by 0.5 mL at 2 and 6 months after initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     I.M. Children &ge;9 years and Adults &le;45 years: 0.5 mL followed by 0.5 mL at 2 and 6 months after initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      CDC recommended immunization schedule:",
"     </i>",
"     Administer first dose at age 11-12 years; begin series in females aged 13-26 years or males 13-21 years if not previously vaccinated. Males may also be vaccinated through 26 years of age. Minimum interval between first and second doses is 4 weeks; the minimum interval between first and third doses is 24 weeks. Inadequate doses or doses received following a shorter than recommended dosing interval should be repeated. The HPV vaccine series should be completed with the same product whenever possible (CDC, 2007; CDC, 60[50] 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3001516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/51/29493?source=see_link\">",
"      see \"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Immunization regimen:",
"     </b>",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3011343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gardasil&reg;: HPV 6 L1 protein 20 mcg, HPV 11 L1 protein 40 mcg, HPV 16 L1 protein 40 mcg, and HPV 18 L1 protein 20 mcg per 0.5 mL (0.5 mL) [contains aluminum, polysorbate 80; manufactured using",
"     <i>",
"      S. cerevisiae",
"     </i>",
"     (baker's yeast)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3000504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3001517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Shake suspension well before use. Inject the entire dose I.M. into the deltoid region of the upper arm or higher anterolateral thigh area. Observe for syncope for 15 minutes following administration. If the vaccine series is interrupted and only one dose was given, administer the second dose as soon as possible and give the third dose &ge;12 weeks later. If the vaccine series is interrupted and the first two doses were given, administer the third dose as soon as possible. The HPV vaccine series should be completed with the same product whenever possible.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3000508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Females &ge;9 years and &le;26 years of age: Prevention of cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma",
"     <i>",
"      in situ",
"     </i>",
"     , and vulvar, vaginal, cervical, or anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Males &ge;9 years and &le;26 years of age: Prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11; anal cancer caused by HPV types 16 and 18, and anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Females &ge;9 years and &le;26 years of age: Prevention of anal cancer caused by HPV types 16 and 18; anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Females &ge;9 years and &le;45 years of age: Prevention of cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma",
"     <i>",
"      in situ",
"     </i>",
"     , vulvar, vaginal, or cervical intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Males &ge;9 years and &le;26 years of age: Prevention of anal cancer caused by HPV types 16 and 18; anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18; genital warts caused by HPV types 6 and 11",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for females and males 11-12 years of age; catch-up vaccination is recommended for females 13-26 years of age and males 13-21 years of age. Males 22-26 years may also be vaccinated. The ACIP also recommends routine vaccination for men who have sex with men (MSM) through 26 years of age (CDC, 59[20], 2010; CDC, 60[50], 2011). Vaccination is also recommended for immunocompromised persons or MSM through 26 years of age who were not previously vaccinated when they were younger. Although not specifically recommended for their profession, health care providers within the recommended age groups should also receive the HPV vaccine (CDC, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9518288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil&reg;) may be confused with Papillomavirus vaccine types 16, 18 (Cervarix&reg;)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3000557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (12% to 28%), fever (8% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Pain (61% to 84%), erythema (17% to 25%), swelling (14% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 4%), malaise (1%), insomnia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2% to 7%), diarrhea (3% to 4%), vomiting (1% to 2%), toothache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Bruising (3%), pruritus (3%), hematoma (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1%), myalgia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain (3%), cough  (2%), nasal congestion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute disseminated encephalomyelitis, alopecia areata, anaphylactic/anaphylactoid reaction, appendicitis, arrhythmia, arthritis, asthma, autoimmune hemolytic anemia and other autoimmune diseases, bronchospasm, cellulitis, cerebrovascular accident, chills, DVT, fatigue, gastroenteritis, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, hyper-/hypothyroidism, injection site joint movement impairment, ITP, JIA, lymphadenopathy, motor neuron disease, pancreatitis, paralysis, pelvic inflammatory disease, pulmonary embolus, RA, renal failure (acute), seizure, sepsis, syncope (may result in falls with injury or be associated with tonic-clonic movements), transverse myelitis, urticaria, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3000514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to papillomavirus recombinant vaccine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3000553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use. Patients who develop hypersensitivity after administration should not receive further dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human papillomavirus (HPV) infection: There is no evidence that individuals already infected with HPV will be protected; those already infected with 1 or more HPV types were protected from disease in the remaining HPV types. Not for the treatment of active disease; will not protect against diseases not caused by HPV vaccine types 6, 11, 16, and 18.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids)); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;9 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Not recommended for use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Yeast: Product may contain yeast.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC 60[2], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Maximum efficacy: The entire 3-dose regimen should be completed for maximum efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3000561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3000509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3000510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not observed in animal studies. In clinical trials, women who were found to be pregnant before the completion of the 3-dose regimen were instructed to defer any remaining dose until pregnancy resolution. Pregnancies detected within 30 days of vaccination had a higher rate of congenital anomalies (pyloric stenosis, congenital megacolon, congenital hydronephrosis, hip dysplasia, club foot) than the placebo group. Pregnancies with onset beyond 30 days of vaccination had a rate of congenital anomalies consistent with the general population. Overall, the type of teratogenic events were the same as those generally observed for this age group.  Administration of the vaccine in pregnancy is not recommended; until additional information is available, the vaccine series (or completion of the series) should be delayed until pregnancy is completed. Pregnancy testing is not required prior to administration of the vaccine (CDC, 2013).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;display:inline\">",
"     A registry has been established for women exposed to the HPV vaccine during pregnancy (1-800-986-8999).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3000512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3000513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     It is not known if this vaccine is excreted into breast milk. Infants had a higher incidence of acute respiratory illness when breast-fed by mothers within 30 days postvaccination. The manufacturer recommends that caution be exercised when administering papilloma virus vaccine to nursing women. Lactating women may receive vaccine (CDC, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3001519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Gynecologic screening exam, papillomavirus test as per current guidelines; screening for HPV is not required prior to vaccination and screening for cervical cancer should continue as recommended following vaccination. Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Females: Gynecologic screening exam, papillomavirus test; screening for cervical cancer should continue per current guidelines following vaccination",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gardasil (AR, AT, AU, BE, BG, CH, CN, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3001513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Contains inactive human papillomavirus (HPV) proteins HPV 6 L1, HPV 11 L1, HPV 16 L1, and HPV 18 L1 which produce neutralizing antibodies to prevent cervical cancer, cervical adenocarcinoma, cervical, vaginal and vulvar neoplasia, and genital warts caused by HPV.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9559927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Peak seroconversion was observed 1 month following the last dose of vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Not well defined; at least 5 years",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013,\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2013, 62(1):9-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/23364303/pubmed\" id=\"23364303\" target=\"_blank\">",
"        23364303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(20):626-9. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm?s_cid=mm5920a4_e\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm?s_cid=mm5920a4_e",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR-2):1-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/17380109/pubmed\" id=\"17380109\" target=\"_blank\">",
"        17380109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee on Immunization Practices (ACIP), 2011,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      ,  2011, 60(50):1705-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/22189893/pubmed\" id=\"22189893\" target=\"_blank\">",
"        22189893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einstein MH, Baron M, Levin MJ, et al, &ldquo;Comparison of the Immunogenicity and Safety of Cervarix&reg; and Gardasil&reg; Human Papillomavirus (HPV) Cervical Cancer Vaccines in Healthy Women Aged 18-45 Years,&rdquo;",
"      <i>",
"       Hum Vaccin",
"      </i>",
"      , 2009, 5(10):507-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/19684472/pubmed\" id=\"19684472\" target=\"_blank\">",
"        19684472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      FUTURE II Study Group, &ldquo;Quadrivalent Vaccine Against Human Papillomavirus to Prevent High-Grade Cervical Lesions,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(19):1915-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/17494925/pubmed\" id=\"17494925\" target=\"_blank\">",
"        17494925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garland SM, Hernandez-Avila M, Wheeler CM, et al, &ldquo;Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(19):1928-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/17494926/pubmed\" id=\"17494926\" target=\"_blank\">",
"        17494926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giuliano AR, Palefsky JM, Goldstone S, et al, &ldquo;Efficacy of Quadrivalent HPV Vaccine Against HPV Infection and Disease in Males,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2011, 364(5):401-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koutsky LA, Ault KA, Wheeler CM, et al, &ldquo;A Controlled Trial of a Human Papillomavirus Type 16 Vaccine,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(21):1645-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/12444178/pubmed\" id=\"12444178\" target=\"_blank\">",
"        12444178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mao C, Koutsky LA, Ault KA, et al, &ldquo;Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      ,  2006, 107(1):18-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/16394035/pubmed\" id=\"16394035\" target=\"_blank\">",
"        16394035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mu&ntilde;oz N, Manalastas R Jr, Pitisuttithum P, et al, &ldquo;Safety, Immunogenicity, and Efficacy of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine in Women Aged 24-45 Years: A Randomised, Double-Blind Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9679):1949-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/19493565/pubmed\" id=\"19493565\" target=\"_blank\">",
"        19493565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Advisory Committee on Immunization (NACI), &ldquo;Statement on Human Papillomavirus Vaccine. An Advisory Committee Statement (ACS),&rdquo;",
"      <i>",
"       Can Commun Dis Rep",
"      </i>",
"      , 2007, 33(ACS-2):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/17520773/pubmed\" id=\"17520773\" target=\"_blank\">",
"        17520773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reisinger KS, Block SL, Collins-Ogle M, et al, &ldquo;Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(6):1142-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/20439595/pubmed\" id=\"20439595\" target=\"_blank\">",
"        20439595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saslow D, Castle PE, Cox JT, et al,  &ldquo;American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors,&rdquo;",
"      <i>",
"       CA Cancer J Clin",
"      </i>",
"      , 2007, 57(1):7-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/17237032 /pubmed\" id=\"17237032 \" target=\"_blank\">",
"        17237032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinbrook R, &ldquo;The Potential of Human Papillomavirus Vaccines,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(11):1109-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/16540608/pubmed\" id=\"16540608\" target=\"_blank\">",
"        16540608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vesikari T, Van Damme P, Lindblad N, et al, &ldquo;An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine Given Concomitantly With Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccine in Healthy Adolescents 11 to 17 Years of Age,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2010, 29(4):314-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/35/43574/abstract-text/19952980/pubmed\" id=\"19952980\" target=\"_blank\">",
"        19952980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9054 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-197.136.42.3-15C0CD54DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43574=[""].join("\n");
var outline_f42_35_43574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000502\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994263\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000506\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000566\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3001516\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011343\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000504\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3001517\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000508\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518288\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000557\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000514\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000553\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299822\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000561\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000509\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000510\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000512\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000513\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3001519\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038887\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3001513\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559927\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9054\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9054|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/49/17169?source=related_link\">",
"      Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/51/29493?source=related_link\">",
"      Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_35_43575="Burn class adult child";
var content_f42_35_43575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Modified Lund-Browder chart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 719px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numbers refer to the percent body surface area burned.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43575=[""].join("\n");
var outline_f42_35_43575=null;
var title_f42_35_43576="Routine prenatal ultrasonography as a screening tool";
var content_f42_35_43576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Routine prenatal ultrasonography as a screening tool",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Anna K Sfakianaki, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Joshua Copel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43576/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/35/43576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal ultrasonography is a common procedure. In the United States, the Centers for Disease Control and Prevention reported that a prenatal ultrasound examination was performed in 67 percent of live births in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/1\">",
"     1",
"    </a>",
"    ]. The percent was higher in white women than in black women. Whether all obstetrical patients should undergo ultrasound screening and whether such screening improves pregnancy outcome is controversial. Currently, the American College of Obstetricians and Gynecologists (ACOG), the American Institute for Ultrasound in Medicine (AIUM), and the American College of Radiology (ACR) support the use of ultrasound when there is a specific medical indication and advises against casual use of ultrasonography during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. ACOG also stated that the benefits and limitations of ultrasonography should be discussed with all patients, and performance of the procedure is reasonable in patients who request it.",
"   </p>",
"   <p>",
"    Many other countries have developed local guidelines for the practice of prenatal ultrasonography and most offer at least one mid-trimester ultrasound examination as part of standard prenatal care, although worldwide obstetric practice varies.",
"   </p>",
"   <p>",
"    An evidence-based discussion of the application of ultrasound to an unselected obstetric population as a screening tool will be presented here. The use of prenatal ultrasonography for specific obstetrical indications is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=see_link\">",
"     \"Ultrasound examination in obstetrics and gynecology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180873986\">",
"    <span class=\"h1\">",
"     OBJECTIVES OF PRENATAL SCREENING ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of routine fetal ultrasound examination is to obtain information that will enable delivery of optimal antenatal care and thus the best possible outcomes for mother and fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/6\">",
"     6",
"    </a>",
"    ]. The following information is obtained: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=see_link\">",
"     \"Ultrasound examination in obstetrics and gynecology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal viability",
"     </li>",
"     <li>",
"      Gestational age and expected date of delivery",
"     </li>",
"     <li>",
"      Number of fetuses. Chorionicity should be determined in multiple gestations.",
"     </li>",
"     <li>",
"      Fetal biometry",
"     </li>",
"     <li>",
"      Fetal survey to detect congenital anomalies, including signs suggestive of aneuploidy",
"     </li>",
"     <li>",
"      Assessment of amniotic fluid volume",
"     </li>",
"     <li>",
"      Placental location (2",
"      <sup>",
"       nd",
"      </sup>",
"      trimester)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRITERIA FOR A GOOD SCREENING TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for a good screening test are described in the table (",
"    <a class=\"graphic graphic_table graphicRef78115 \" href=\"mobipreview.htm?38/47/39675\">",
"     table 1",
"    </a>",
"    ). In general, screening tests should have high sensitivity, although this may come at the expense of lowered specificity. They should identify individuals with an important disease or condition and be cost-effective, allowing for control of health care costs by identifying disease early and treating before the consequences of the disease are overwhelming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ESTIMATION OF GESTATIONAL AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the expected date of delivery (EDD) is of the utmost importance in obstetrics so that misdiagnosis (and inappropriate intervention) of preterm and postdates pregnancy can be avoided. Traditionally the EDD is defined as 280 days from the onset of the last menstrual period (LMP) in women with regular 28 day cycles. It is used in clinical decision-making, in perinatal research, as well as in personal planning for the expectant",
"    <span class=\"nowrap\">",
"     mother/couple.",
"    </span>",
"   </p>",
"   <p>",
"    Ample",
"    evidence has accumulated that routine ultrasound examination results in more accurate assessment of the EDD than LMP dating or physical examination, even in women with regular and certain menstrual dates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/7\">",
"     7",
"    </a>",
"    ]. A representative example of this evidence is illustrated by a trial that randomly assigned 648 women at &lt;17 weeks of gestation to receive or not receive an ultrasound examination at their first prenatal visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/8\">",
"     8",
"    </a>",
"    ]. None of the women had an indication for the test. All had an ultrasound examination at 18 to 22 weeks of gestation. Women assigned to routine early ultrasound were less likely to need adjustment of their EDD at the 18 to 22 week ultrasound examination and had more positive feelings about their pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dating a pregnancy by LMP is the favored method, especially when ultrasound measurements are concordant with the EDD derived from the LMP. Different algorithms that incorporate ultrasound into the assignment of EDD have emerged. &nbsp;In general, it is reasonable to use the sonographically derived EDD if it differs from that calculated using the last menstrual period (LMP) by more than five to seven days in the first trimester and by more than 10 to 14 days in the second trimester or by 8 percent. In the third trimester, a three-week discrepancy between LMP dating and ultrasound dating is allowed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link&amp;anchor=H22#H22\">",
"     \"Prenatal assessment of gestational age\", section on 'Assigning the EDD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When ultrasound is used to change the EDD after the first trimester, a follow-up ultrasound should be considered after two weeks or more to confirm the revised dates, and to exclude the possibility of a fetal growth disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduction in intervention for postterm pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound-based determination of EDD has been shown to improve diagnosis and thus reduce intervention for postterm pregnancy. This was illustrated by a Cochrane review of 11 trials of routine ultrasound in early pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/9\">",
"     9",
"    </a>",
"    ]. Routine use of early ultrasound and the subsequent adjustment of the EDD led to a significant reduction in inductions of labor for postterm pregnancy (RR 0.59, 95% CI 0.42-0.83). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=see_link\">",
"     \"Postterm pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Included in this Cochrane review is the Alesund randomized controlled trial, which evaluated the effect of routine ultrasound examinations at 18 and 32 weeks of gestation on the accuracy of dating and pregnancy outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/10\">",
"     10",
"    </a>",
"    ]. A low risk population of 1628 women was randomly assigned to ultrasound screening plus routine antenatal care or routine antenatal care alone. The major findings from this trial were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasound screening reduced the incidence of induced labor for postterm pregnancy by 70 percent, and also reduced the incidence of induction for all causes",
"     </li>",
"     <li>",
"      Ultrasound screening resulted in some better neonatal outcomes: The proportion of five minute Apgar scores &lt;8 and the need for positive pressure ventilation were both lower in the screened group. These findings were significant, although the absolute number of neonates in each of the groups was small. The reason for these improvements in neonatal outcome is not apparent from the data, but may be related to decreased complications associated with postdatism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these studies found that ultrasound determination of EDD as late as 34 weeks can reduce the number of pregnancies eventually diagnosed as postterm, other randomized trials looking specifically at the timing of the examination demonstrated that first trimester ultrasound in a low-risk population was more effective than second trimester ultrasound in decreasing postterm pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reduction in diagnosis of IUGR",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early ultrasound examination serves as an important baseline against which later examinations are compared for the evaluation of fetal growth. The assessment of appropriate fetal or neonatal size is based upon the expected weight for gestational age. If gestational age is overestimated, then an appropriately grown",
"    <span class=\"nowrap\">",
"     fetus/neonate",
"    </span>",
"    may be incorrectly classified as growth restricted (IUGR) or small for gestational age (SGA). As an example, a trial including 4997 women with reliable menstrual history randomly assigned them to calculation of EDD by LMP alone versus by biparietal diameter (BPD) on second trimester ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/12\">",
"     12",
"    </a>",
"    ]. Pregnancies dated by ultrasound showed a decrease in the incidence of both antenatally suspected IUGR and postnatally diagnosed SGA. The reduction in these diagnoses might have been an effect of the improved dating of the pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reduction in use of tocolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus for the upper gestational age limit for initiating tocolysis in an attempt to prevent preterm delivery, although antenatal steroids for acceleration of fetal maturation are not administered after 34 weeks. However, at some threshold gestational age the morbidity and mortality related to prematurity are too low to justify the potential maternal and fetal complications and costs associated with the inhibition of labor, so tocolytic therapy is withheld. Thus, accurate assessment of gestational age is important so as not to inappropriately initiate tocolysis for late preterm labor. A policy of routine ultrasound screening has been associated with a statistically significant reduction in the use of tocolytic therapy, presumably because more accurate dating reduced the number of false positive preterm labor cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF TWIN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major benefit of routine ultrasound screening is early, reliable identification of twin pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/10,14-16\">",
"     10,14-16",
"    </a>",
"    ]. Randomized clinical trials comparing routine second trimester ultrasound examination with ultrasound performed for clinical indications have shown that a significant number of twin pregnancies are not recognized until the third trimester or delivery in women who do not undergo routine ultrasound examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=see_link\">",
"     \"Twin pregnancy: Prenatal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the Cochrane review of 11 trials of ultrasound screening in early pregnancy found that twins were diagnosed earlier in routinely scanned pregnancies and ultrasound in early pregnancy significantly reduced the failure to detect multiple pregnancy by 24 weeks of gestation (RR 0.07, 95% CI 0.03 to 0.17) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/17\">",
"     17",
"    </a>",
"    ]. By comparison, the RADIUS (Routine Antenatal Diagnostic Imaging with Ultrasound Study) study of over 15,000 gravidas reported that in women who did not have a routine second trimester ultrasound examination 38 percent of twin pregnancies remained unrecognized until after 26 weeks of gestation, and 13 percent of twins were not diagnosed until delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/16\">",
"     16",
"    </a>",
"    ]. There were no twin pregnancies missed on ultrasound examination.",
"   </p>",
"   <p>",
"    Similar findings were reported by the Helsinki trial, a prospective randomized trial of 9310 women of which 4691 underwent screening ultrasound between 16 and 20 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/15\">",
"     15",
"    </a>",
"    ]. All twin pregnancies were detected before 21 weeks of gestation in the screened group, versus 76.3 percent in the control group. Moreover, the perinatal mortality rate of twins in the screened group was",
"    <span class=\"nowrap\">",
"     27.8/1000",
"    </span>",
"    compared with",
"    <span class=\"nowrap\">",
"     65.8/1000",
"    </span>",
"    in the control group, although these were small numbers and did not reach statistical significance. Retrospective series have also suggested improved neonatal outcome with early diagnosis of twin pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DETECTION OF CONGENITAL ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of routine ultrasound screening to detect fetal anomalies is an unselected population is highly controversial. Over 30 studies have evaluated this question, and numerous reviews have attempted to summarize them critically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/18\">",
"     18",
"    </a>",
"    ]. The largest trials comparing screened and nonscreened groups are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Second trimester",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Helsinki Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Helsinki Trial, performed from 1986 to 1987, randomly assigned 4691 women to screening ultrasound at 16 to 20 weeks to look for fetal anomalies and compared their outcome to 4619 controls who underwent ultrasound examination if obstetrically indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/19\">",
"     19",
"    </a>",
"    ]. Ultrasounds were performed at one of two hospitals, 95 percent of all pregnant women in the Helsinki metropolitan area agreed to participate, and only four women were lost to follow up (but mortality data were complete). Seventy-seven percent of women in the control group underwent ultrasound examination sometime during pregnancy.",
"   </p>",
"   <p>",
"    Routine second trimester ultrasound screening was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly increased detection of fetal anomalies.",
"     </li>",
"     <li>",
"      A significant reduction in the perinatal mortality rate (PMR",
"      <span class=\"nowrap\">",
"       4.6/1000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       9.0/1000",
"      </span>",
"      in controls) because elective termination of anomalous fetuses resulted in fewer fetal and neonatal deaths due to congenital anomalies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, the rate of detection of malformations was 36 percent in the City Hospital and 77 percent at the University Hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     RADIUS Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Routine Antenatal Diagnostic Imaging with Ultrasound (RADIUS) trial was the first randomized trial of routine obstetrical ultrasound screening in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/16,20\">",
"     16,20",
"    </a>",
"    ]. It included over 15,000 women randomly assigned to either screening ultrasounds at both 15 to 22 weeks and 31 to 35 weeks or to ultrasound for obstetrical indications only. Forty five percent of the control group had at least one ultrasound.",
"   </p>",
"   <p>",
"    Routine second trimester ultrasound screening was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly increased detection of fetal anomalies (34.8 versus 11 percent). Of these anomalies, one-half were detected prior to 24 weeks of gestation in the screened group (16.6 percent of the total cohort of anomalous fetuses).",
"     </li>",
"     <li>",
"      No improvement in any perinatal outcome under study, including mortality, preterm birth, birth weight, and neonatal morbidity (retinopathy of prematurity, bronchopulmonary dysplasia, need for mechanical ventilation, necrotizing enterocolitis, intraventricular hemorrhage).",
"     </li>",
"     <li>",
"      No increase in the number of abortions performed for fetal anomalies, which was the same in both groups",
"     </li>",
"     <li>",
"      No improvement in survival among anomalous fetuses. Antenatal detection of fetal anomalies did not improve survival over that with postnatal diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted in the Helsinki trial, detection rates were significantly higher in tertiary facilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Eurofetus Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Eurofetus study of 1999 is the largest study of routine ultrasonographic examination in unselected population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/21\">",
"     21",
"    </a>",
"    ]. Women were routinely scanned by trained sonologists at 18 to 22 weeks in 61 centers across Europe.",
"   </p>",
"   <p>",
"    Results of routine second trimester ultrasound screening were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitivity for detection of all anomalies was 56.2 percent",
"     </li>",
"     <li>",
"      The detection rate was higher for major (73.7 percent) than for minor (45.7 percent) anomalies, and higher for anomalies of the central nervous system (88.3 percent) and the urinary tract (88.5 percent) than for cardiac abnormalities (38.8 percent of major cardiac and 20.8 percent of minor cardiac anomalies were detected).",
"     </li>",
"     <li>",
"      Overall, 44 percent of anomalies and 55 percent of severe anomalies were detected before 24 weeks. Cardiac defects and cleft",
"      <span class=\"nowrap\">",
"       lip/palate",
"      </span>",
"      were diagnosed later in pregnancy than abnormalities of the CNS, urinary tract, or musculoskeletal systems.",
"     </li>",
"     <li>",
"      The rate of live births for mothers carrying fetuses with anomalies was lower than that of mothers carrying fetuses with no detected anomalies because many pregnancies with anomalous fetuses were electively terminated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Analysis of trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several important factors need to be considered when analyzing these data: prevalence of anomalies, characteristics of the population, the setting in which the ultrasound was performed, and study design.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prevalence of anomalies",
"      </strong>",
"      &mdash; Detection rates for anomalies are dependent upon the prevalence of each anomaly in the population studied, and prevalence is highly dependent upon the quality of follow-up achieved. For example, how thoroughly were aborted fetuses, stillbirths, and neonates examined for presence of anomalies? Were autopsies and x-rays performed when appropriate? Were neonates examined by a physician with additional expertise in dysmorphology? How many neonates underwent noninvasive studies with incidental discovery of a congenital anomaly? Some anomalies are not diagnosed until early childhood, was there examination of pediatric records to identify these children?",
"      <br/>",
"      <br/>",
"      The table shows that anomaly prevalence rates reported in the literature range from 0.3 to 3.2 percent (",
"      <a class=\"graphic graphic_table graphicRef75346 \" href=\"mobipreview.htm?28/14/28910\">",
"       table 2",
"      </a>",
"      ). Studies with low prevalence rates likely represent incomplete follow up, thus detection rates and published sensitivities are not necessarily reliable. The last column in the table corrects for the differing prevalence rates and standardizes sensitivity rates for each study. The adjusted overall cumulative sensitivity becomes 40 percent, with the Eurofetus detection rate climbing to almost 70 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Population characteristics",
"      </strong>",
"      &mdash; Characteristics of the population studied also affect both detection rates and the applicability of data to other populations. For example, two of the RADIUS trial's main inclusion criteria were that the patients have private obstetrical care and that they be indifferent to the possibility of termination of pregnancy. In fact, after all exclusions, only 28 percent of the eligible women actually participated in the study. One consequence of these selection criteria is that women who wished to undergo ultrasound examination, including those who might consider termination in the event of fetal anomaly, did not elect to participate. Thus, the observation that 71 percent of women with ultrasound-detected anomalies prior to 24 weeks decided to continue their pregnancies is not generalizable to an unselected population of pregnant women.",
"      <br/>",
"      <br/>",
"      In this respect, data from the Helsinki trial, which included 95 percent of women in the area, more reliably describe the consequences of detecting fetal anomalies antenatally. The Helsinki trial reported that birth rates of anomalous fetuses were low due to termination of many of these pregnancies.",
"      <br/>",
"      <br/>",
"      Another important aspect of the RADIUS trial is that approximately 85 percent of the population ultimately had an identifiable indication for ultrasound. Seventy percent of women were excluded prior to randomization, primarily because potential indications for ultrasound examination were present, and 50 percent of the remaining (enrolled) patients developed indications during the trial.",
"     </li>",
"     <li>",
"      <strong>",
"       Setting",
"      </strong>",
"      &mdash; The setting in which the ultrasound is performed significantly affects detection rates. Factors relating to the setting involve the equipment available as well as the skill and experience of the examiners. Both the RADIUS trial and the Helsinki trial showed that examinations performed in hospital or tertiary care settings identified more anomalies than those performed in office-based or community centers. They also showed that ultrasound was more effective when performed by experienced operators.",
"     </li>",
"     <li>",
"      <strong>",
"       Study design",
"      </strong>",
"      &mdash; Studies are designed and powered to detect differences in their main outcome variables. Investigators choose study outcomes based upon their clinical significance and relevance to the question at hand. The endpoints chosen by the investigators of the RADIUS trial were associated with prematurity, rather than with anomalies and their consequences. RADIUS was not powered to detect differences in secondary outcome measures associated with the diagnosis of anomalies, such as impact on immediate survival, long-term neonatal outcomes in anomalous fetuses, and economic and social implications. In fact, the survival rate for infants with acute life-threatening anomalies was higher in the screened group (75 percent) than in the nonscreened group (52 percent). Although this was not statistically significant, this was likely due to the very small sample size.",
"      <br/>",
"      <br/>",
"      Other investigators have found that patients with cardiac anomalies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/22\">",
"       22",
"      </a>",
"      ] and specifically hypoplastic left heart [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/23\">",
"       23",
"      </a>",
"      ] and transposition of the great arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/24\">",
"       24",
"      </a>",
"      ] have better outcomes when the diagnosis is made prenatally rather than postnatally. The data regarding long-term outcome for prenatally diagnosed anomalies of the renal system are conflicting and limited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of fetal anomalies in the first trimester is limited by the small size of the fetus and ongoing fetal development, which can result in later development of markers suggestive of an underlying abnormality (eg, hydramnios related to esophageal atresia). Nevertheless, ultrasound technology is rapidly progressing and assessment of fetal anatomy in the first trimester is becoming a reality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of studies that determined the detection rate of fetal anomalies after first and second trimester ultrasound screening found first trimester median sensitivity was 52 percent (range 16 to 84 percent) and second trimester median sensitivity was 83 percent (range 47 to 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/26\">",
"     26",
"    </a>",
"    ]. Most of the studies performed both transvaginal and transabdominal examinations and used a two-stage protocol whereby each pregnancy was scanned in both the first and second trimesters.",
"   </p>",
"   <p>",
"    Fetal cardiac anatomy can also be evaluated in the first trimester by trained specialists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/29\">",
"     29",
"    </a>",
"    ]. The use of nuchal translucency measurement in the first trimester as a marker for the detection of congenital heart disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2857?source=see_link\">",
"     \"First trimester cystic hygroma and increased nuchal translucency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DETECTION OF ANEUPLOIDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is most sensitive for the detection of aneuploidy when used in conjunction with serum screening. The combination of the two modalities, especially when performed in the first trimester, can detect over 90 percent of fetuses with Down syndrome, as well as fetuses with other aneuploidies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/27/22969?source=see_link\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum screening protocols are dependent upon accurate estimation of gestational age. The majority of abnormal tests recalculated based on corrected EDD are normal. Thus, routine ultrasound estimation of gestational age may reduce the number of women who have anxiety caused by false positive results in serum screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27257?source=see_link&amp;anchor=H22#H22\">",
"     \"Laboratory issues related to maternal serum screening for Down syndrome\", section on 'Method of gestational age determination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PERINATAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine ultrasound examination in late pregnancy appears to confer no benefit to an unselected population. Although early identification of growth-restricted fetuses allows for closer surveillance and earlier intervention in case of decompensation, the use of ultrasound in the third trimester to screen for fetal growth disturbance in low risk women has not been effective for reliably detecting these fetuses or improving outcome. This was illustrated in a trial in which an unselected population of women underwent routine early ultrasonography to establish EDD and then were randomly assigned to 32 week sonographic fetal growth assessment or routine care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/30\">",
"     30",
"    </a>",
"    ]. Perinatal outcomes were similar for both groups. Ultrasonographic detection of fetal growth restriction is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Cochrane review of eight studies including 27,024 unselected or low risk women also showed no difference in obstetric, antenatal or neonatal interventions between women undergoing routine late ultrasound examination (after 24 weeks) and those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/31\">",
"     31",
"    </a>",
"    ]. Moreover, there was no difference in perinatal outcome measures, such as admission to a neonatal intensive care unit, birthweight &lt;10th percentile, or perinatal mortality.",
"   </p>",
"   <p>",
"    Another randomized trial not included in the Cochrane review showed that routine third trimester ultrasound at both 30 to 32 and 36 to 37 weeks increased the number of fetuses suspected of growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/32\">",
"     32",
"    </a>",
"    ]. Although fewer SGA births occurred in the screened group, there was no reduction in the frequency of NICU admission and suspicion of growth restriction led to a high rate of intervention: the rate of intervention was 31 percent in the study group versus 17 percent in controls receiving routine care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DOPPLER ULTRASOUND SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of Doppler to obstetrical ultrasound provides information on function in addition to form. Doppler velocimetry of the fetal circulation is used to assess vascular impedance, especially in the setting of suspected growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/33\">",
"     33",
"    </a>",
"    ]. Multiple trials have evaluated the use of Doppler ultrasound as a screening tool in low risk women. These have consistently found neither maternal nor fetal benefit, which is in contrast to the proven benefit in high-risk pregnancies.",
"   </p>",
"   <p>",
"    As an example, a Cochrane review of routine Doppler ultrasound in pregnancy analyzed five controlled trials including 14,185 low",
"    <span class=\"nowrap\">",
"     risk/unselected",
"    </span>",
"    women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/34\">",
"     34",
"    </a>",
"    ]. Routine umbilical artery Doppler velocimetry applied in various protocols was not associated with any differences in short-term clinical outcomes, including cesarean delivery, birth weight and perinatal morbidity and mortality, nor did the procedure lead to increased antenatal, obstetric or neonatal interventions. These studies also indicated that the overall incidence of abnormal Doppler was low (1.7 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Resource utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall effect of routine screening on the health care system is yet to be determined. A small number of reports have analyzed the cost-benefit ratio of screening low risk women with obstetrical ultrasound.",
"   </p>",
"   <p>",
"    The authors of the RADIUS trial concluded that routine ultrasound was not cost-effective and that offering the procedure would place a burden on health care systems. However, the authors neglected to take into consideration all of the outcome measures in the study. As an example, although overall perinatal mortality was not changed, there was a significantly higher rate of detection of anomalies in the screened group. The study was not powered to analyze what effect this detection rate had on secondary outcomes, namely utilization of abortion services or reduction in the neonatal costs for pregnancies that were not continued. In addition, the trial found a significant reduction in induction for postterm pregnancy and in the use of tocolysis, but these effects were not evaluated in the cost analysis.",
"   </p>",
"   <p>",
"    Because of these criticisms, investigators not involved in the RADIUS study performed a complex cost-benefit analysis of routine second-trimester ultrasound using data from the RADIUS trial and taking into consideration all of the findings of the trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/35\">",
"     35",
"    </a>",
"    ]. Costs were estimated for each type of fetal anomaly and projected for the follow up each would need in neonatal life, and savings from decreased use of tocolysis and decreased diagnosis of postterm pregnancy were calculated. This analysis concluded that routine ultrasound screening was associated with significant savings, but only if the ultrasonography was performed in tertiary care centers, where experience and efficiency were greatest.",
"   </p>",
"   <p>",
"    The Helsinki Trial also addressed the use of antenatal cares services in its trial of routine ultrasound screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/36\">",
"     36",
"    </a>",
"    ]. Ultrasound screening slightly, but significantly, increased the number of routine antenatal visits (12.9 versus 12.6). However, it also reduced the need for specialist services, primarily by improving the accuracy of gestational age estimation and removing questions regarding pregnancy dating. There were no differences in hospital admissions.",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis on the same data set suggested that second trimester screening with ultrasound is cost-effective, at least in a society with a publicly financed health system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/37\">",
"     37",
"    </a>",
"    ]. The absolute cost per ultrasound was $86, which included the cost of equipment, staff, travel, and lost working time. When the costs of screening-induced examinations and procedures (repeat ultrasounds, amniocenteses, etc) were added, the cost per ultrasound rose to $102. Cost savings were calculated based upon decreased utilization of health services and visits, and amounted to $182 per ultrasound, yielding a net saving of $80 per patient in the screened group. The gross cost of avoiding one perinatal death was $21,938, as based upon the decreased perinatal mortality rate reported in that trial. Stated differently, if the malformation rate was",
"    <span class=\"nowrap\">",
"     2.95/1000,",
"    </span>",
"    and the cost per ultrasound was $102, the cost to identify a single fetus with a malformation was $34,620, a number which is much lower than the amount spent during the hospitalization of a neonate with a congenital anomaly. The Helsinki data cannot be directly applied to the United States health care system when one considers that costs in general are much greater in the United States. Importantly, this evaluation assumes the availability and acceptability of termination of pregnancy.",
"   </p>",
"   <p>",
"    A randomized trial from an urban center in South Africa also looked at the costs of routine ultrasound screening and perinatal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/38\">",
"     38",
"    </a>",
"    ]. The study group consisted of patients without risk factors for congenital anomalies referred for ultrasound at 18 to 24 weeks of gestation, while the control group had routine care only; both groups could be referred for additional scans as indicated. Women in the control group were more likely to be diagnosed with postdate pregnancies and undergo amniocenteses for confirmation of lung maturity; however, the overall incidence of major adverse perinatal outcomes was comparable in the two groups. Routine sonography was associated with increased costs that were not accounted for by improved outcomes.",
"   </p>",
"   <p>",
"    A systematic review of studies examining cost and cost-effectiveness in screening ultrasound concluded that the available data were of poor quality and that data could not be summarized to draw useful conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/39\">",
"     39",
"    </a>",
"    ]. The authors commented specifically that charges were examined instead of costs, and maternal costs and long-term costs were not examined effectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of obstetric ultrasound is well established and is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27592?source=see_link\">",
"     \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\"",
"    </a>",
"    .) Safety is not a significant variable in the decision to recommend routine obstetric ultrasound or not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ethical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ethical concept of autonomy guides the physician in providing patients with as much information as they need to make educated choices about their medical care. It implies a respect for patients' individual belief systems and patients' ability to choose among appropriate options in health care. Engaging patients in a thoughtful discussion of the benefits and limitations of routine ultrasound respects the concept of autonomy by providing patients with the information they need to make these choices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/18,40\">",
"     18,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Women's views",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is very attractive to women because it provides early visual confirmation of pregnancy, contact with their babies, and usually reassures about fetal well-being [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/41\">",
"     41",
"    </a>",
"    ]. However, anxiety may be heightened when the scan shows a problem, especially when findings of uncertain clinical significance are noted. A Swedish trial examined this issue by randomly assigning women to ultrasound examination at 12 to 14 weeks of gestation plus risk assessment for Down Syndrome or routine ultrasound alone at 15 to 20 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/42\">",
"     42",
"    </a>",
"    ]. Anxiety levels were assessed by questionnaire at baseline, 24 weeks of gestation and two months after delivery. There were no statistically significant differences in the two groups; in fact, anxiety levels decreased in both groups as pregnancy progressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/29/37331?source=see_link\">",
"       \"Patient information: Prenatal care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the discussion above, routine early ultrasound is beneficial in an unselected population because of better estimation of gestational age resulting in significantly reduced frequency of labor induction for postterm pregnancy and use of tocolysis for suspected preterm labor.",
"   </p>",
"   <p>",
"    In addition, first trimester ultrasound examination can lead to earlier detection of clinically unsuspected fetal malformations (including aneuploidies) and earlier detection of multiple pregnancy. These effects have not been shown to improve ultimate fetal outcome, although studies have lacked power to assess for secondary outcomes. Improvements in technology, increasing experience, and refinements in visualization should make the detection of anomalies in the first trimester more efficient at a time when termination of pregnancy is possible and private.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Second trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;If one screening ultrasound examination is performed, the optimal timing is at 18 to 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43576/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The large number of trials addressing ultrasound screening in the second trimester of pregnancy primarily focused upon detection of anomalies. The value (ie, utility) that individual patients place on birth, or avoidance of birth, of a child with an unsuspected anomaly needs to be incorporated into any cost-benefit equation of this issue, but is not routinely assessed. The Eurofetus trial likely approaches the most accurate sensitivity rates for ultrasound in the detection of anomalies (approximately 50 to 70 percent).",
"   </p>",
"   <p>",
"    Overall, these data suggest that it is both ethical and cost-effective to offer routine screening in the second trimester for detection of fetal anomalies and that the ultrasound examination should be carried out by experienced and thorough practitioners. The examination should be performed at a gestational age that allows for good visualization of anatomy, and thus will have a high yield for anomalies. At the same time, it should be done at a gestational age that is early enough to allow completion of prenatal diagnostic procedures (eg, fetal karyotype, additional imaging studies) while legal termination of pregnancy is possible, if desired. As discussed above, this is at 18 to 20 weeks of gestation.",
"   </p>",
"   <p>",
"    Ultrasound in the second trimester is also effective when used to establish EDD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Third trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available data does not support the routine use of ultrasound in the third trimester to screen low risk women.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Martin, J, et al., Births: Final data for 2002. National Vital Statistics Reports 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/2\">",
"      ACOG Committee on Ethics. ACOG Committee Opinion. Number 297, August 2004. Nonmedical use of obstetric ultrasonography. Obstet Gynecol 2004; 104:423.",
"     </a>",
"    </li>",
"    <li>",
"     AIUM Practice Guidelines for the Performance of Obstetric Ultrasound Examinations. October 1, 2007.",
"    </li>",
"    <li>",
"     ACR Practice Guideline for the Performance of Obstetrical Ultrasound. October 1, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/5\">",
"      Abuhamad AZ, ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin, clinical management guidelines for obstetrician-gynecologists number 98, October 2008 (replaces Practice Bulletin number 58, December 2004). Ultrasonography in pregnancy. Obstet Gynecol 2008; 112:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/6\">",
"      Salomon LJ, Alfirevic Z, Berghella V, et al. Practice guidelines for performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol 2011; 37:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/7\">",
"      Mongelli M, Wilcox M, Gardosi J. Estimating the date of confinement: ultrasonographic biometry versus certain menstrual dates. Am J Obstet Gynecol 1996; 174:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/8\">",
"      Crowther CA, Kornman L, O'Callaghan S, et al. Is an ultrasound assessment of gestational age at the first antenatal visit of value? A randomised clinical trial. Br J Obstet Gynaecol 1999; 106:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/9\">",
"      Whitworth M, Bricker L, Neilson JP, Dowswell T. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev 2010; :CD007058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/10\">",
"      Eik-Nes SH, Salvesen KA, Okland O, Vatten LJ. Routine ultrasound fetal examination in pregnancy: the 'Alesund' randomized controlled trial. Ultrasound Obstet Gynecol 2000; 15:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/11\">",
"      Bennett KA, Crane JM, O'shea P, et al. First trimester ultrasound screening is effective in reducing postterm labor induction rates: a randomized controlled trial. Am J Obstet Gynecol 2004; 190:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/12\">",
"      Waldenstr&ouml;m U, Axelsson O, Nilsson S. Ultrasonic dating of pregnancies: effect on incidence of SGA diagnoses. A randomised controlled trial. Early Hum Dev 1992; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/13\">",
"      LeFevre ML, Bain RP, Ewigman BG, et al. A randomized trial of prenatal ultrasonographic screening: impact on maternal management and outcome. RADIUS (Routine Antenatal Diagnostic Imaging with Ultrasound) Study Group. Am J Obstet Gynecol 1993; 169:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/14\">",
"      Hughey MJ, Olive DL. Routine ultrasound scanning for the detection and management of twin pregnancies. J Reprod Med 1985; 30:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/15\">",
"      Saari-Kemppainen A, Karjalainen O, Yl&ouml;stalo P, Heinonen OP. Ultrasound screening and perinatal mortality: controlled trial of systematic one-stage screening in pregnancy. The Helsinki Ultrasound Trial. Lancet 1990; 336:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/16\">",
"      Ewigman BG, Crane JP, Frigoletto FD, et al. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group. N Engl J Med 1993; 329:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/17\">",
"      Neilson JP. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev 2000; :CD000182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/18\">",
"      Levi S. Ultrasound in prenatal diagnosis: polemics around routine ultrasound screening for second trimester fetal malformations. Prenat Diagn 2002; 22:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/19\">",
"      Saari-Kemppainen A, Karjalainen O, Yl&ouml;stalo P, Heinonen OP. Fetal anomalies in a controlled one-stage ultrasound screening trial. A report from the Helsinki Ultrasound Trial. J Perinat Med 1994; 22:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/20\">",
"      Crane JP, LeFevre ML, Winborn RC, et al. A randomized trial of prenatal ultrasonographic screening: impact on the detection, management, and outcome of anomalous fetuses. The RADIUS Study Group. Am J Obstet Gynecol 1994; 171:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/21\">",
"      Grandjean H, Larroque D, Levi S. The performance of routine ultrasonographic screening of pregnancies in the Eurofetus Study. Am J Obstet Gynecol 1999; 181:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/22\">",
"      Friedberg MK, Silverman NH, Moon-Grady AJ, et al. Prenatal detection of congenital heart disease. J Pediatr 2009; 155:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/23\">",
"      Tworetzky W, McElhinney DB, Reddy VM, et al. Improved surgical outcome after fetal diagnosis of hypoplastic left heart syndrome. Circulation 2001; 103:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/24\">",
"      Bonnet D, Coltri A, Butera G, et al. Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality. Circulation 1999; 99:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/25\">",
"      Clayton DB, Brock JW 3rd. Prenatal ultrasonography: implications for pediatric urology. J Pediatr Urol 2011; 7:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/26\">",
"      Timor-Tritsch IE, Fuchs KM, Monteagudo A, D'alton ME. Performing a fetal anatomy scan at the time of first-trimester screening. Obstet Gynecol 2009; 113:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/27\">",
"      Syngelaki A, Chelemen T, Dagklis T, et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn 2011; 31:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/28\">",
"      Ebrashy A, El Kateb A, Momtaz M, et al. 13-14-week fetal anatomy scan: a 5-year prospective study. Ultrasound Obstet Gynecol 2010; 35:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/29\">",
"      Lombardi CM, Bellotti M, Fesslova V, Cappellini A. Fetal echocardiography at the time of the nuchal translucency scan. Ultrasound Obstet Gynecol 2007; 29:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/30\">",
"      Duff GB. A randomized controlled trial in a hospital population of ultrasound measurement screening for the small for dates baby. Aust N Z J Obstet Gynaecol 1993; 33:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/31\">",
"      Bricker L, Neilson JP, Dowswell T. Routine ultrasound in late pregnancy (after 24 weeks' gestation). Cochrane Database Syst Rev 2008; :CD001451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/32\">",
"      McKenna D, Tharmaratnam S, Mahsud S, et al. A randomized trial using ultrasound to identify the high-risk fetus in a low-risk population. Obstet Gynecol 2003; 101:626.",
"     </a>",
"    </li>",
"    <li>",
"     Arbeille, P, Leguyader, P, Fignon, A. Fetal Hemodynamics and Flow Velocity Indices. In: Doppler Ultrasound in Obstetrics and Gynecology, Copel, JA (Ed), Raven Press, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/34\">",
"      Bricker L, Neilson JP. Routine doppler ultrasound in pregnancy. Cochrane Database Syst Rev 2000; :CD001450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/35\">",
"      Vintzileos AM, Ananth CV, Smulian JC, et al. Routine second-trimester ultrasonography in the United States: a cost-benefit analysis. Am J Obstet Gynecol 2000; 182:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/36\">",
"      Saari-Kemppainen A. Use of antenatal care services in a controlled ultrasound screening trial. Acta Obstet Gynecol Scand 1995; 74:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/37\">",
"      Leivo T, Tuominen R, Saari-Kemppainen A, et al. Cost-effectiveness of one-stage ultrasound screening in pregnancy: a report from the Helsinki ultrasound trial. Ultrasound Obstet Gynecol 1996; 7:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/38\">",
"      Geerts LT, Brand EJ, Theron GB. Routine obstetric ultrasound examinations in South Africa: cost and effect on perinatal outcome--a prospective randomised controlled trial. Br J Obstet Gynaecol 1996; 103:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/39\">",
"      Roberts T, Henderson J, Mugford M, et al. Antenatal ultrasound screening for fetal abnormalities: a systematic review of studies of cost and cost effectiveness. BJOG 2002; 109:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/40\">",
"      Chervenak FA, McCullough LB. Ethical dimensions of ultrasound screening for fetal anomalies. Ann N Y Acad Sci 1998; 847:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/41\">",
"      Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/42\">",
"      Georgsson Ohman S, Saltvedt S, Grunewald C, Waldenstr&ouml;m U. Does fetal screening affect women's worries about the health of their baby? A randomized controlled trial of ultrasound screening for Down's syndrome versus routine ultrasound screening. Acta Obstet Gynecol Scand 2004; 83:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43576/abstract/43\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 101: Ultrasonography in pregnancy. Obstet Gynecol 2009; 113:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 430 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43576=[""].join("\n");
var outline_f42_35_43576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180873986\">",
"      OBJECTIVES OF PRENATAL SCREENING ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRITERIA FOR A GOOD SCREENING TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ESTIMATION OF GESTATIONAL AGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduction in intervention for postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reduction in diagnosis of IUGR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reduction in use of tocolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IDENTIFICATION OF TWIN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DETECTION OF CONGENITAL ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Second trimester",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Helsinki Trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - RADIUS Trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Eurofetus Trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Analysis of trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      First trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DETECTION OF ANEUPLOIDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PERINATAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DOPPLER ULTRASOUND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Resource utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Safety issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ethical considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Women's views",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      First trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Second trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Third trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/47/39675\" title=\"table 1\">",
"      Criteria for a screening test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/14/28910\" title=\"table 2\">",
"      Screening for fetal anomalies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27592?source=related_link\">",
"      Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2857?source=related_link\">",
"      First trimester cystic hygroma and increased nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27257?source=related_link\">",
"      Laboratory issues related to maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=related_link\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=related_link\">",
"      Ultrasound examination in obstetrics and gynecology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_35_43577="Initial management of blood glucose in type 2 diabetes mellitus";
var content_f42_35_43577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial management of blood glucose in type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/35/43577/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43577/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/35/43577/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43577/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/35/43577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43577/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/35/43577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with type 2 diabetes mellitus includes education, evaluation for microvascular and macrovascular complications, normalization of glycemia, minimization of cardiovascular and other long-term risk factors, and avoidance of drugs that can aggravate abnormalities of insulin or lipid metabolism. Although several studies have noted remissions of type 2 diabetes mellitus that may last several years, most patients require continuous treatment in order to maintain normal or near-normal glycemia. Treatments to achieve normoglycemia focus on increasing insulin secretion, responsiveness, or both, or decreasing the rate of carbohydrate absorption.",
"   </p>",
"   <p>",
"    Methods used to control blood glucose in patients with newly-diagnosed type 2 diabetes are reviewed here. Further management of persistent hyperglycemia and other therapeutic issues, such as the frequency of monitoring and evaluation for microvascular and macrovascular complications, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Degree of glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achieving near normal blood glucose concentrations markedly reduces the risk of microvascular and macrovascular complications in type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improved glycemic control also improves the risk of microvascular complications in patients with type 2 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef52273 \" href=\"mobipreview.htm?36/32/37389\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/1\">",
"     1",
"    </a>",
"    ]. Every 1 percent drop in A1C is associated with improved outcomes with no threshold effect. To date, no randomized clinical trial has convincingly demonstrated a beneficial effect of intensive therapy on macrovascular outcomes in type 2 diabetes. Target A1C goals in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. Glycemic targets are generally set somewhat higher for older patients and those with comorbidities or a limited life expectancy and little likelihood of benefit from intensive therapy. Glycemic goals are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Glycemic control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H19#H19\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Glycemic targets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiovascular risk factor management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to glycemic control, vigorous cardiac risk reduction (smoking cessation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , blood pressure control, reduction in serum lipids, diet, and exercise) should be a top priority for all patients with type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .) However, in spite of evidence that aggressive risk factor reduction lowers the risk of both micro- and macrovascular complications in patients with diabetes, the vast majority of patients do not achieve recommended goals for A1C, blood pressure control, and management of dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Adequacy of care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides contributing to microvascular and macrovascular disease, hyperglycemia adversely and reversibly affects both insulin resistance and insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Weight reduction, diet, and exercise can all be used to improve glycemic control, although the majority of patients with type 2 diabetes will require medication over the course of their diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1667131\">",
"    <span class=\"h2\">",
"     Weight reduction",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary modification can improve many aspects of type 2 diabetes, including obesity, hypertension, and insulin release and responsiveness. The improvement in glycemic control is related both to the degree of caloric restriction and weight reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Modest weight reduction may also improve liver function in nonalcoholic steatohepatitis, which is associated with insulin resistance and type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=see_link&amp;anchor=H53583857#H53583857\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\", section on 'Weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immediate effect of caloric restriction is not well understood but may be related to depletion of hepatic glycogen stores, thereby reducing hepatic glucose output, the main determinant of fasting blood glucose. However, this benefit will persist only if negative calorie balance and weight reduction are continued.",
"   </p>",
"   <p>",
"    Several studies have evaluated the long-term efficacy of diet (alone or with exercise) in patients with newly diagnosed type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .) In the UKPDS, for example, all patients were given a low calorie, low fat, high complex carbohydrate diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/7\">",
"     7",
"    </a>",
"    ]. After three years, only 3 percent of those treated with diet alone had achieved and maintained the desired fasting blood glucose concentration below 108",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Furthermore, the mean glucose value was substantially higher with diet alone than with diet plus an oral hypoglycemic drug or insulin.",
"   </p>",
"   <p>",
"    The likelihood of a successful response to diet is determined in large part by the initial fasting blood glucose. In the UKPDS, the degree of weight loss required to normalize the fasting blood glucose was 10 kg (16 percent of initial body weight) if the initial value was 108 to 144",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6 to 8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    versus 22 kg (35 percent) if the initial value was 216 to 252",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (12 to 14",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef78027 \" href=\"mobipreview.htm?1/25/1438\">",
"     figure 2",
"    </a>",
"    ). Of note, any degree of weight loss is likely to improve glycemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decrease the need for medications.",
"   </p>",
"   <p>",
"    Despite the clear benefit of weight loss, only a small percentage of patients with type 2 diabetes are able to attain and maintain substantial weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. This difficulty results from both limited success in long-term adherence to calorie-restricted diets, plus an apparent effect of weight loss in lowering the metabolic rate, thereby retarding further weight loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link&amp;anchor=H5#H5\">",
"     \"Dietary therapy for obesity\", section on 'Maintenance of weight loss'",
"    </a>",
"    .) There are, however, impressive successes reported with intensive dietary intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1667087\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy for weight loss may be effective in patients with type 2 diabetes, but generally is associated with high dropout rates due to medication side effects and is not recommended as primary therapy for diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1667108\">",
"    <span class=\"h3\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical treatment of obese patients with diabetes results in the largest degree of sustained weight loss and, in parallel, improvements in blood glucose control. However, longer-term follow-up is required before bariatric surgery procedures can be routinely recommended for the treatment of recent onset, obesity-related type 2 diabetes. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H1665282#H1665282\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Surgical treatment of obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular exercise is also beneficial in type 2 diabetes, independent of weight loss. It leads to improved glycemic control due to increased responsiveness to insulin; it can also delay the progression of impaired glucose tolerance to overt diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/12\">",
"     12",
"    </a>",
"    ]. These effects are directly due to exercise, but concurrent weight reduction can play a contributory role. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .) However, only a fraction of patients with type 2 diabetes are able to maintain a regular exercise regimen. In one 10-year study, for example, compliance with regular exercise fell from 80 percent at six weeks to less than 50 percent at three months and to less than 20 percent at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intensive lifestyle modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive lifestyle intervention programs involving weight loss, physical activity, and behavior modification are more likely to be successful in improving long-term glycemic control than traditional diabetes support and education programs. In the Look AHEAD trial, which will continue for 11.5 years, 5145 individuals with type 2 diabetes were randomly assigned to an intensive lifestyle intervention or standard diabetes education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/13\">",
"     13",
"    </a>",
"    ]. The intensive intervention includes caloric restriction (maximum 30 percent calories from fat, minimum 15 percent protein, and the remainder from carbohydrates, in the form of liquid meal replacements, frozen food entrees, or structured meal plans), moderate-intensity physical activity (goal 175 minutes weekly), and weekly group or individual sessions with registered dietitians, behavioral psychologists, and exercise specialists. If weight loss goals were not achieved in the first six months, a weight loss medication (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced behavioral strategies were initiated.",
"   </p>",
"   <p>",
"    After one year, the intensive group lost an average of 8.6 percent of their initial weight, and mean A1C decreased from 7.3 to 6.6 percent, whereas the control group lost 0.7 percent and A1C decreased from 7.3 to 7.2 percent. In addition, the use of glucose lowering medications decreased in the intensive group and blood pressure, HDL, and triglyceride concentrations improved more than in the control group. At year four, the intensive group maintained a mean weight loss of 4.7 percent compared with 1.1 percent in the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/14\">",
"     14",
"    </a>",
"    ].&nbsp;Mean A1C&nbsp;levels were 7.1 and 7.2 percent, respectively. In an exploratory analysis of the four year data, complete (normalization of fasting glucose without antihyperglycemic medication) or partial (transition from fasting glucose &gt;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    to 100 to 126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6 to 7.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    and to A1C of 5.7 to 6.5 percent) remission of diabetes was more common in patients in the intensive lifestyle modification group (7.3 versus 2.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with early stage, well controlled diabetes were most likely to benefit from the intensive lifestyle intervention.",
"   </p>",
"   <p>",
"    The improvement in weight and glycemia did not reduce the occurrence of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/16\">",
"     16",
"    </a>",
"    ]. Although the data are currently being analyzed, possible reasons for this finding include the lower than expected rates of cardiovascular events in both groups, improved overall cardiovascular risk factor treatment with medical therapy (antihypertensives, statins), and enrollment of a relatively healthy patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Psychological interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 2 diabetes often experience significant stress related to the many self-care responsibilities to optimize glycemic control (lifestyle modifications, medication, and self-monitoring of blood glucose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/18\">",
"     18",
"    </a>",
"    ]. Concurrent depression may also interfere with self-care. Psychotherapy reduces psychological distress and improves glycemic control in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/19\">",
"     19",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/20\">",
"     20",
"    </a>",
"    ], studies. In a meta-analysis of 12 trials of patients with type 2 diabetes randomly assigned to psychological intervention or usual care, mean A1C was lower in the intervention group (pooled mean difference -0.32, 95% CI -0.57 to -0.07; absolute decrease in A1C was 0.76 percent [-1.32 to -0.18]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/19\">",
"     19",
"    </a>",
"    ]. Measures of psychological distress were also significantly lower in the intervention group, but there were no differences in weight control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEDICATIONS FOR INITIAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26275125\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic abnormalities that characterize type 2 diabetes worsen with age. Early institution of treatment for diabetes, at a time when the A1C is not significantly elevated, is associated with improved glycemic control over time and decreased long-term complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/21\">",
"     21",
"    </a>",
"    ]. Pharmacologic therapy is often not initiated soon enough, resulting in poor glycemic control. In the absence of specific contraindications, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    as initial therapy in most patients. We suggest initiating metformin at the time of diabetes diagnosis, along with consultation for lifestyle intervention (",
"    <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"mobipreview.htm?7/63/8176\">",
"     algorithm 1",
"    </a>",
"    ). For highly motivated patients with A1C near target (ie, &lt;7.5 percent), a three to six month trial of lifestyle modification before initiating metformin is reasonable. Metformin was chosen for initial therapy because of glycemic efficacy, absence of weight gain and hypoglycemia, general tolerability, and favorable cost. The majority of guidelines recommend metformin as first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Metformin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other options for initial therapy in those with contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are available (",
"    <a class=\"graphic graphic_table graphicRef56876 \" href=\"mobipreview.htm?3/22/3437\">",
"     table 1",
"    </a>",
"    ). In the absence of many high-quality head-to-head comparison trials, our suggestions are based upon clinical trial evidence and clinical experience in achieving glycemic targets. The long-term benefits and risks of using one approach over another are unknown. In patients with contraindications to metformin, we suggest a shorter acting sulfonylurea, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    . Insulin is also a reasonable option for initial therapy in patients who present with symptomatic or poorly controlled diabetes or in patients in whom it is difficult to distinguish type 1 from type 2 diabetes. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Insulin'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who are intolerant of or are not candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or sulfonylureas,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    is a reasonable alternative, particularly in a patient with chronic kidney disease at risk for hypoglycemia.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     Pioglitazone",
"    </a>",
"    may also be considered in patients with specific contraindications to metformin and sulfonylureas. However, the risk of heart failure, fractures, and the potential increased risk of bladder cancer raises the concern that the overall risks and cost of pioglitazone may exceed its benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other oral and injectable agents, such as GLP-1 agonists, alpha-glucosidase inhibitors, or DPP-IV inhibitors may be appropriate initial therapy for some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. However, limited clinical experience, lower or overall equivalent effectiveness compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , insulin, and sulfonylureas, higher cost,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    side effects reduce their appeal as initial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combinations of these drugs are often necessary to achieve optimal results. The balance among efficacy in lowering A1C, side effects, and costs must be carefully weighed in considering which drugs or combinations to choose. Avoiding insulin, the most potent of all hypoglycemic medications, at the expense of poorer glucose control and greater side effects and cost, is not likely to benefit the patient in the long-term. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach is largely consistent with American and European guidelines. A consensus statement regarding the management of hyperglycemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) was developed in 2006 and has been updated regularly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/22,25,26\">",
"     22,25,26",
"    </a>",
"    ]. The 2006 and 2009 consensus guidelines were developed with the intent of providing guidance (&ldquo;guidelines&rdquo;) for clinicians to select from the increasing number of classes and drugs within classes. The algorithm was therefore prescriptive, making distinctions among classes and drugs based upon specific, stated characteristics of the",
"    <span class=\"nowrap\">",
"     classes/drugs,",
"    </span>",
"    and value judgments (",
"    <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"mobipreview.htm?7/63/8176\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The most important, acknowledged problem with the algorithm was (and is) the absence of direct comparative effectiveness data. The selection of drugs in the 2009",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    consensus guideline was based upon clinical trial evidence and clinical experience in achieving glycemic targets, with the recognition that there is a paucity of many high-quality head to head drug comparison trials and trials with important clinical endpoints, such as effects on complications. In addition, the guidelines emphasized the importance of individualizing the choice of medications for the treatment of diabetes.",
"   </p>",
"   <p>",
"    The 2012 Position Statement also acknowledges the absence of primary source evidence, provides an excellent review of the characteristics of the classes and drugs, and chooses specifically to provide a non-prescriptive approach, encouraging clinicians to integrate the current evidence in the context of patient-specific factors, including patient preferences, needs, and values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/22\">",
"     22",
"    </a>",
"    ]. There is little difference between the 2009 and 2012 documents with regard to the assessment of the medications. The",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    recommends",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (in the absence of contraindications) as initial therapy in most patients. In patients with contraindications to metformin, the 2012",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    consensus guideline suggests either a",
"    <span class=\"nowrap\">",
"     sulfonylurea/glinide,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , or a DPP-IV inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/22,25,26\">",
"     22,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the individual medications considered in the algorithm follows below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of contraindications,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is the first choice for oral treatment of type 2 diabetes. It generally reduces A1C by 1.5 percentage points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In contrast with most other antidiabetic drugs, metformin often leads to modest weight reduction or weight stabilization (",
"    <a class=\"graphic graphic_figure graphicRef55968 \" href=\"mobipreview.htm?43/19/44350\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/7,30,31\">",
"     7,30,31",
"    </a>",
"    ]. Furthermore, obese patients in the UKPDS who were assigned initially to receive metformin rather than sulfonylurea or insulin therapy had a decreased risk of the aggregate diabetes-related endpoint and all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/32\">",
"     32",
"    </a>",
"    ]. During the post-interventional observation period of the UKPDS, reductions in the risk of macrovascular complications were maintained in the metformin group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H11#H11\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'UKPDS'",
"    </a>",
"    .) The cardiovascular benefits of metformin in the UKPDS need to be confirmed before metformin can be recommended to reduce cardiovascular disease.",
"   </p>",
"   <p>",
"    Gastrointestinal side effects are common, but",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    monotherapy does not usually cause hypoglycemia. Metformin can rarely cause lactic acidosis, and because of the potentially fatal outcome of this side effect, metformin should not be administered when conditions predisposing to lactic acidosis are present. Such conditions include impaired renal function (plasma creatinine above 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [124",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in women and 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in men), decreased tissue perfusion or hemodynamic instability due to infection or other causes, concurrent liver disease or alcohol abuse, and heart failure. Factors predisposing to lactic acidosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link&amp;anchor=H9#H9\">",
"     \"Metformin in the treatment of diabetes mellitus\", section on 'Predisposing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are about to receive intravenous iodinated contrast material (with potential for contrast-induced renal failure) or undergo a surgical procedure (with potential compromise of circulation) should have",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    held until renal function and circulation can be established (normal urine output, normal serum creatinine, and no physical exam evidence of fluid overload or circulatory compromise). Serum creatinine is typically assessed two to three days after contrast administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link&amp;anchor=H7#H7\">",
"     \"Metformin in the treatment of diabetes mellitus\", section on 'Lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sulfonylureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylureas are the oldest class of oral hypoglycemic agents. They are moderately effective, lowering blood glucose concentrations by 20 percent and A1C by 1 to 2 percent. However, their effectiveness decreases over time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major adverse effect of sulfonylureas is hypoglycemia. Before beginning a sulfonylurea, the patient should be instructed about the symptoms and treatment of hypoglycemia. Hypoglycemia induced by long-acting sulfonylureas may be severe and is often prolonged in the absence of appropriate therapy. Risk factors for hypoglycemia include increasing age, alcohol abuse, poor nutrition, and renal insufficiency. Shorter acting sulfonylureas, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    , are less likely to cause hypoglycemia than the older, long-acting sulfonylureas (",
"    <a class=\"graphic graphic_table graphicRef56701 \" href=\"mobipreview.htm?16/49/17180\">",
"     table 2",
"    </a>",
"    ), and therefore are the preferred sulfonylureas, especially in older patients. Initiation of sulfonylurea therapy is also associated with weight gain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=see_link&amp;anchor=H5#H5\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of sulfonylurea is primarily dependent upon cost, risk of hypoglycemia, and local availability, since the efficacy of the available drugs is similar. In a patient who is not a candidate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or who cannot tolerate metformin, we suggest a shorter-duration sulfonylurea, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Meglitinides",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     Repaglinide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    are short-acting glucose-lowering drugs that act similarly to the sulfonylureas and have similar or slightly less efficacy in decreasing glycemia. Meglitinides are pharmacologically distinct from sulfonylureas and may be used in patients who have allergy to sulfonylurea medications. They have a similar risk for weight gain as sulfonylureas but possibly less risk of hypoglycemia. However, they are considerably more expensive than sulfonylureas, and have no therapeutic advantage over these other drugs that warrant the added cost. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/21/11606?source=see_link\">",
"     Nateglinide",
"    </a>",
"    is hepatically metabolized, with renal excretion of active metabolites. With decreased renal function, the accumulation of active metabolites and hypoglycemia has occurred. This drug must therefore be used cautiously in this setting, if at all.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     Repaglinide",
"    </a>",
"    is principally metabolized by the liver, with less than 10 percent renally excreted. Dose adjustments with this agent do not appear to be necessary in patients with renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7865?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of hyperglycemia in diabetics with end-stage renal disease\", section on 'Meglitinides'",
"    </a>",
"    .) In addition, repaglinide is somewhat more effective in lowering A1C than nateglinide. Thus, repaglinide could be considered as initial therapy in a patient with chronic kidney disease who is intolerant of sulfonylureas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thiazolidinediones,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , lower blood glucose concentrations by increasing insulin sensitivity. The first drug in this class, troglitazone, was removed from the market in the United Kingdom and the United States because of relatively rare, but severe, idiosyncratic hepatic injury that was either fatal or necessitated liver transplantation. Hepatotoxicity does not appear to occur with rosiglitazone and pioglitazone. However, some meta-analyses have questioned the safety of rosiglitazone with regard to the risk of myocardial infarction. In 2010, the European Medicines Agency suspended sales of rosiglitazone, owing to concern regarding cardiovascular safety and the availability of alternative therapies, including pioglitazone, that do not have the same concerns. At the same time, the US Food and Drug Administration restricted its use to patients with type 2 diabetes who cannot achieve adequate glycemic control with other medications, including pioglitazone. Subsequently, in 2011, the French and German Medicines Agencies suspended the use of pioglitazone because of the potential increased risk of bladder cancer and the concern that the overall risks of pioglitazone exceed its benefits. The European Medicines Agency, the US Food and Drug Administration, and Japanese regulators withheld action pending results of ongoing review of the data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H12774482#H12774482\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Bladder cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As monotherapy, thiazolidinediones are probably somewhat less effective in lowering glycemia than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , lowering A1C by 0.5 to 1.4 percentage points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/33\">",
"     33",
"    </a>",
"    ]. They are also associated with more weight gain and fluid retention than metformin, and are considerably more expensive than generic sulfonylureas and metformin. Drugs in this class are not recommended in patients with symptomatic heart failure and are contraindicated in patients with New York Heart Association class III or IV heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, we do not generally choose thiazolidinediones for initial therapy and reserve their use for second-line treatment in combination with other anti-diabetic medications where synergistic effects can lower A1C substantially. If a thiazolidinedione is used,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    is recommended because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     DPP-IV inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     Sitagliptin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    are DPP-IV inhibitors that are approved as initial pharmacologic therapy for the treatment of type 2 diabetes. However, because of modest glucose lowering effectiveness, expense, and limited clinical experience, DPP-IV inhibitors are more commonly used as a second agent in those who do not respond to a single agent (such as a sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or a thiazolidinedione), or as a third agent when dual therapy with metformin and a sulfonylurea does not provide adequate glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H23#H23\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'DPP-IV inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     Sitagliptin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    can be considered as monotherapy in patients who are intolerant of, or have contraindications to,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylureas, or thiazolidinediones. As an example, sitagliptin might be a good choice as initial therapy in a patient with chronic kidney disease at risk for hypoglycemia. However, given the unknown consequences of long-term DPP-IV inhibition, we prefer to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    in this situation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=see_link&amp;anchor=H13#H13\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'DPP-4 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    are currently the only DPP-IV inhibitors available for the treatment of type 2 diabetes in the United States, vildagliptin is available in several countries, and other DPP-IV inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    ) are in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H23#H23\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'DPP-IV inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucagon-like peptide 1 agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    are glucagon-like peptide 1 (GLP-1) analogs that are administered subcutaneously. They are approved in the United States by the FDA for the treatment of type 2 diabetes in patients not sufficiently controlled with diet, exercise, or oral agents. Exenatide (requires two daily injections or a once weekly injection) or liraglutide (one daily injection) could be considered as add-on drugs for patients with type 2 diabetes who are poorly controlled on maximal doses of one or two oral agents. We do not recommend the use of exenatide or liraglutide as monotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=see_link\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alpha-glucosidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because they act by a different mechanism, the alpha-glucosidase inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/0/3077?source=see_link\">",
"     miglitol",
"    </a>",
"    , have additive hypoglycemic effects in patients receiving diet, sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , or insulin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/1\">",
"     1",
"    </a>",
"    ]. This class of drugs is less potent than the sulfonylureas or metformin, lowering A1C by only 0.5 to 0.8 percentage points.",
"   </p>",
"   <p>",
"    The main side effects, which may limit their acceptance, are flatulence and diarrhea. Although these drugs have been studied as monotherapy for initial treatment of diabetes, we do not consider them to be usual first-line therapy because of reduced efficacy, expense, and poor tolerance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although historically insulin has been used for type 2 diabetes only when inadequate glycemic control persists despite oral agents and lifestyle intervention, there are increasing data to support using insulin earlier and more aggressively in type 2 diabetes. By inducing near normoglycemia with intensive insulin therapy, both endogenous insulin secretion and insulin sensitivity improve; this results in better glycemic control, which can then be maintained with diet, exercise, and oral hypoglycemics for many months thereafter. Insulin may cause weight gain and hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin therapy in type 2 diabetes is initially aimed at increasing basal insulin concentrations (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"mobipreview.htm?19/63/20467\">",
"     algorithm 2",
"    </a>",
"    ). Patients with type 2 diabetes require relatively large doses of insulin, compared with those needed for type 1 diabetes. Insulin preparations, insulin regimens, and timing of dosing are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Comparison of initial therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few high quality head-to-head comparison trials of the available oral agents.",
"   </p>",
"   <p>",
"    In A Diabetes Outcome Progression Trial (ADOPT), 4360 recently diagnosed patients with type 2 diabetes were randomly assigned to monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the four-year evaluation, 40 percent of the subjects in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      group had an A1C value less than 7 percent, as compared with 36 percent in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      group and 26 percent in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      group.",
"     </li>",
"     <li>",
"      At the four-year evaluation, insulin sensitivity was significantly better in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      group compared with the other two groups, whereas insulin secretion was slightly but significantly better in the rosiglitazone and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      groups compared with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      group.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"       Rosiglitazone",
"      </a>",
"      caused greater increases in weight, peripheral edema, and concentrations of LDL cholesterol. There was also an unexpected increase in fractures in women taking rosiglitazone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H18#H18\">",
"       \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Safety'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       Glyburide",
"      </a>",
"      caused weight gain and a greater incidence of hypoglycemia and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      more gastrointestinal side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The study was limited by a high rate of withdrawal of study participants. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    had greater durability as monotherapy than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    , its benefit over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    was fairly small and of uncertain clinical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    as initial therapy is supported by a meta-analysis of 140 trials and 26 observational studies evaluating the effects of oral or injectable diabetes medications as monotherapy and in combination with other oral agents or insulin on intermediate outcomes (A1C, body weight, lipid profiles) and adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/36\">",
"     36",
"    </a>",
"    ]. Older agents (metformin and second generation sulfonylureas) (",
"    <a class=\"graphic graphic_table graphicRef56701 \" href=\"mobipreview.htm?16/49/17180\">",
"     table 2",
"    </a>",
"    ) had similar efficacy in reducing A1C values (approximately one percentage point) and other cardiovascular risk factors (blood pressure, lipids, body weight) compared with newer agents (thiazolidinediones, meglitinides, and GLP-1 receptor agonists). In this and a subsequent meta-analysis, metformin reduced A1C levels more than DPP-IV inhibitor monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/35/43577/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although each diabetes medication is associated with adverse events,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    was associated with fewer episodes of hypoglycemia compared with sulfonylureas and less edema, congestive heart failure, and weight gain compared with thiazolidinediones. In addition, metformin is less expensive and has more clinical practice experience than thiazolidinediones.",
"   </p>",
"   <p>",
"    Combination therapy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Treatment options'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Efficacy of combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=see_link\">",
"       \"Patient information: Treatment for type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of specific contraindications, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      as initial therapy in most patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Medications for initial therapy'",
"      </a>",
"      above.) Insulin can also be considered a first-line therapy for all patients with type 2 diabetes, particularly patients presenting with A1C &gt;10 percent, fasting plasma glucose &gt;250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      random glucose consistently &gt;300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (16.7",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      or ketonuria. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Insulin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"       \"Insulin therapy in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We suggest initiating metformin at the time of diabetes diagnosis, along with consultation for lifestyle intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose of metformin should be titrated to its maximally effective dose (usually 2000 to 2500 mg per day in divided doses) over one to two months, as tolerated.",
"      <br/>",
"      <br/>",
"      Metformin should not be administered when conditions predisposing to lactic acidosis are present. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Metformin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link&amp;anchor=H7#H7\">",
"       \"Metformin in the treatment of diabetes mellitus\", section on 'Lactic acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the presence of contraindications to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , we suggest a shorter-duration sulfonylurea (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      ) for initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sulfonylureas'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest initiating lifestyle intervention first, at the time of diagnosis, since the weight gain that often accompanies a sulfonylurea will presumably be less if lifestyle efforts are underway (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, if lifestyle intervention has not produced a significant reduction in symptoms of hyperglycemia or in glucose values after one or two weeks, then the sulfonylurea should be added.",
"     </li>",
"     <li>",
"      In patients who are intolerant of or are not candidates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      or sulfonylureas,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      is a reasonable alternative, particularly in a patient with chronic kidney disease at risk for hypoglycemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Meglitinides'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7865?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of hyperglycemia in diabetics with end-stage renal disease\", section on 'Meglitinides'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Another alternative is a thiazolidinedione, which may be considered in patients with lower initial A1C values or if there are specific contraindications to sulfonylureas. If a thiazolidinedione is to be used as initial therapy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      is preferred because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Thiazolidinediones'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"       \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      DPP-IV inhibitors can be considered as monotherapy in patients who are intolerant of or have contraindications to metformin, sulfonylureas, or thiazolidinediones. As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"       saxagliptin",
"      </a>",
"      might be a good choice as initial therapy in a patient with chronic kidney disease at risk for hypoglycemia. They are, however, more expensive and less potent in lowering glycemia than the glinides, such as repaglinide, which can also be used safely in patients with chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=see_link&amp;anchor=H13#H13\">",
"       \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'DPP-4 inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A potential problem is that patients who are initially thought to have type 2 diabetes may actually have type 1 diabetes, and therefore require insulin as initial therapy. In patients in whom it is difficult to distinguish type 1 from type 2 diabetes, initial treatment with insulin is required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link&amp;anchor=H22#H22\">",
"       \"Insulin therapy in type 2 diabetes mellitus\", section on 'Insulin as initial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Further adjustments of therapy, which should usually be made no less frequently than every three months, are based upon the A1C result (and the results of home glucose monitoring). Target A1C levels in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. A reasonable goal of therapy might be an A1C value of &le;7.0 percent for most patients. Thus, A1C values &gt;7 percent suggest need for further adjustments in the diabetic regimen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H19#H19\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Glycemic targets'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If inadequate control is achieved (A1C remains &gt;7.0 percent), another medication should be added within two to three months of initiation of the lifestyle intervention and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"       \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"       \"Insulin therapy in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/1\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/2\">",
"      Yki-J&auml;rvinen H. Glucose toxicity. Endocr Rev 1992; 13:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/3\">",
"      Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/4\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/5\">",
"      Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985; 61:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/6\">",
"      Wing RR, Blair EH, Bononi P, et al. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/7\">",
"      United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/8\">",
"      Niskanen LK, Uusitupa MI, Sarlund H, et al. Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects. Diabetes Care 1990; 13:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/9\">",
"      Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/10\">",
"      Hadden DR, Blair AL, Wilson EA, et al. Natural history of diabetes presenting age 40-69 years: a prospective study of the influence of intensive dietary therapy. Q J Med 1986; 59:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/11\">",
"      Uusitupa M, Laitinen J, Siitonen O, et al. The maintenance of improved metabolic control after intensified diet therapy in recent type 2 diabetes. Diabetes Res Clin Pract 1993; 19:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/12\">",
"      Schneider SH, Khachadurian AK, Amorosa LF, et al. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 1992; 15:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/13\">",
"      Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/14\">",
"      Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/15\">",
"      Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308:2489.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nih.gov/news/health/oct2012/niddk-19.htm (Accessed on December 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/17\">",
"      Arterburn DE, O'Connor PJ. A look ahead at the future of diabetes prevention and treatment. JAMA 2012; 308:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/18\">",
"      Surwit RS, van Tilburg MA, Zucker N, et al. Stress management improves long-term glycemic control in type 2 diabetes. Diabetes Care 2002; 25:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/19\">",
"      Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/20\">",
"      Williams JW Jr, Katon W, Lin EH, et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med 2004; 140:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/21\">",
"      Colagiuri S, Cull CA, Holman RR, UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 2002; 25:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/22\">",
"      Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/23\">",
"      Bennett WL, Odelola OA, Wilson LM, et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med 2012; 156:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/24\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012; 156:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/25\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/26\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 2008; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/27\">",
"      Desai NR, Shrank WH, Fischer MA, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012; 125:302.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/28\">",
"      Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/29\">",
"      DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/30\">",
"      Hermann LS, Scherst&eacute;n B, Bitz&eacute;n PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/31\">",
"      United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998; 128:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/32\">",
"      Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/33\">",
"      Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89:6068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/34\">",
"      Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/35\">",
"      Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 2006; 355:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/36\">",
"      Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43577/abstract/37\">",
"      Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344:e1369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1779 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43577=[""].join("\n");
var outline_f42_35_43577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Degree of glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiovascular risk factor management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NONPHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1667131\">",
"      Weight reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1667087\">",
"      - Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1667108\">",
"      - Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intensive lifestyle modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Psychological interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEDICATIONS FOR INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26275125\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sulfonylureas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Meglitinides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DPP-IV inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucagon-like peptide 1 agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alpha-glucosidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Comparison of initial therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1779|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?7/63/8176\" title=\"algorithm 1\">",
"      Management type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/63/20467\" title=\"algorithm 2\">",
"      Insulin titration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1779|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/32/37389\" title=\"figure 1\">",
"      Microvascular endpoint and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/25/1438\" title=\"figure 2\">",
"      Weight loss and FBG in NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/19/44350\" title=\"figure 3\">",
"      Drug therapy in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1779|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/22/3437\" title=\"table 1\">",
"      Options for diabetes Tx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/49/17180\" title=\"table 2\">",
"      Sulfonylureas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7865?source=related_link\">",
"      Management of hyperglycemia in diabetics with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=related_link\">",
"      Natural history and management of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_35_43578="ECG late evolution of anterior MI";
var content_f42_35_43578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1280px;\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) late in the evolution of an anterior myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Later stage in the evolution of an acute anterior myocardial infarction. There is a QS pattern in leads V1 to V3 and T wave inversion in leads V2 to V4. The ST segment elevations in these leads have almost disappeared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43578=[""].join("\n");
var outline_f42_35_43578=null;
var title_f42_35_43579="Hodgkin classification";
var content_f42_35_43579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of Hodgkin lymphomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Jackson and Parker",
"      </td>",
"      <td class=\"subtitle1\">",
"       Lukes and Butler",
"      </td>",
"      <td class=\"subtitle1\">",
"       Rye Conference",
"      </td>",
"      <td class=\"subtitle1\">",
"       R.E.A.L. Classification",
"      </td>",
"      <td class=\"subtitle1\">",
"       World Health Organization (WHO) Classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Paragranuloma",
"      </td>",
"      <td>",
"       Lymphocytic and/or histiocytic, nodular",
"      </td>",
"      <td>",
"       Lymphocyte predominance",
"      </td>",
"      <td>",
"       Nodular lymphocyte predominance",
"      </td>",
"      <td>",
"       Nodular lymphocyte predominant HL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphocytic and/or histiocytic, diffuse",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Classical Lymphocyte-rich HL*",
"      </td>",
"      <td>",
"       Lymphocyte-rich classical HL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Granuloma",
"      </td>",
"      <td>",
"       Nodular sclerosis",
"      </td>",
"      <td>",
"       Nodular sclerosis",
"      </td>",
"      <td>",
"       Classical Nodular sclerosis HL",
"      </td>",
"      <td>",
"       Nodular sclerosis classical HL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mixed cellularity",
"      </td>",
"      <td>",
"       Mixed cellularity",
"      </td>",
"      <td>",
"       Classical Mixed cellularity HL",
"      </td>",
"      <td>",
"       Mixed cellularity classical HL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Sarcoma",
"      </td>",
"      <td>",
"       Diffuse fibrosis",
"      </td>",
"      <td>",
"       Lymphocyte depletion",
"      </td>",
"      <td>",
"       Classical Lymphocyte depletion HL",
"      </td>",
"      <td>",
"       Lymphocyte depleted classical HL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reticular",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HL: Hodgkin lymphoma.",
"     <br>",
"      * Includes some L&amp;H nodular cases.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43579=[""].join("\n");
var outline_f42_35_43579=null;
var title_f42_35_43580="HBV pre S-S ORF";
var content_f42_35_43580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    HBV pre-S/S open reading frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 224px; background-image: url(data:image/gif;base64,R0lGODlh1QHgAMQAAP///5mZgJmZfzMzAAAAAICAgEBAQMDAwNDQ0BAQEDAwMPDw8ODg4KCgoCAgILCwsGBgYHBwcM3NwFBQUJCQkGZmPwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADVAeAAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqIESAaytrq+wsbKztLW2t7i5uru8vb6/wMHCw60SqSIBFQLLzM3Oz9DR0tPU1dbX1hXK2Nzd19re4eLj5OXeFQHHAAEClstf7+oAAunH7O7tXvHq9Or3lfu4BEzVz14+SgO1JDxVMNU/hAcFRiRYz+HESAuxZCzVENXDSRuthBzV8dRHSSOp/6QMVdJUMnMwY8rkBm6mTWc1b+rcyTNbRVSriAkdSrSo0aNIkyoFZkye06dQo0qdSrWq1atYs2rdyrWr169YD4g9QGNBgwIFEIxYcIBBmbFkZ5hFqxYAArQN7jxA+wAsHAKACSSo+wJBggQGHBAge2ACgQJlAgsm7MIwYsVkJUegs0ABAQOeIfttAxgABQITABRocBfAggIGJvQtYYDA7AdqA4seU/p06tWtX8eeTaL2bbV5EZSeU4DAZrvER6spfeAzAMGlFSQo4JkyAAiCJ1BwK6L5bjHUrWMnAEA7dwLewScQT14EAwIO6DQAbCCtdNKPeZYXAQqIoFx/4KEV2P8BC4AH2GDlPRZZgAQMWKBdnxWQYHOAMejgZCM4Fl0cBSQQWF7/TfeZAShaB0B1/aHV1lgLLCDCAbWJZt6EBrAogoswolXAjGLVeGOOrtWG4hw22hWBiymisdwIUB7WwAEULCmCARA8cIBnjIEHQVzosUdClQlcmSVtXX65GAOexVgfHLBdmWCUaUz5owEjIOAYfiNS4BmBs0lmZpklQOknYA4EOqgCfVUnGZlw4MjoeXhmqummnHbq6aeghirqqKSWauqpqKaq6qqsturqq7DGKuustNZq66245qrrrrz26uuvwKLAFqUAMHCAdwi0FeyyQzxpGwmDNukaYBcya23/D4oRAMEI9wG25H6AzXntuDU8QAAFJjb55H7Vanfac9IFtdS89NZrL1MkyGtLU/rWwm8uTZ0AHgPgoehAfoq5dR8E9+X3X7/3RizxxPUGDADEs/yLi8a3WEzCAvwpVqC5iJm42ZMO1PYsuSzLcBoEaCm2qJCCAZCAA2iBl1rLPLvgmbraEjiCZ+A9BzIB0vas9NJMN/0HAxQUQEHSaylLG7x2+XhCsmLVlyx5x3IbttOtqix0CY1JmCifI1SH6QhmO7clfjZCGS3ZrD5QI2aJAva2dXd56RwEBoxYW1vLqQyZi91WiLerCZuw49oLJKAAW/i9R9nhyjlcW20HirDu/9mPq/ruCZOf2SOEbgNg7nlmQwhAbfd9LsLBAEReOqpPbou62mfit9iLErYOt3OA1VWbavy5LpgBJu9+qmM4D3kd2weISSyBnWM+ZnfFLdacAzYuX7l1jtGcgPSmGro424auzfwE1ZmYJm3DEz27mfsZAHK7K2OfAAdIwAIa8IAITKACF8jABjrwgRCMoAQnSMEKWvCCGMygBjfIwQ568IMgDKEIR0jCEprwhChMYQKHVQJjIctqKiSVs6JzNxEcrVoxFFW2fFesE40AXAQQVxEwRrEiGvGISEyiEgMgASLGgmP7EoETYeExc6ELaaKrEOncJbckTHGJYAyjGMdIxv8nftEVUPSXFAFWgoEV7HYIC2IPGYafHIbqaIkRGsmgJzeUqWxEdtTUy2IGn/QpaH03yxlqAumpn2URPAAsmg0BQzVGWlJTUJNaJW/EoKuRAAFaMwHXYPi1GxHGhZcshdlw+MMOya9twMNfYJ5TG/Jdb2iUTOUo9LYAvpGAASYanursUgDBRYBwhntT4vx2yx56S5el0B3ceiRMKvnPcpjDGfiOd6w67g90LhodK6HpidORAF0MONzaoKeW1r0ufA9SXhA/4yLcSZOcneidCeJWzesIjzHFi2VtnCVP5llnj9HDZyeoJ6Nbcs0zUzuTArpXne/BJ3wHGF/52HM+Phn/sjnrUygn3NfMuW2PT82hH3buh9H2aGt/Iujf/3AJSJHa9KY4zalOd8rTnvr0p0ANqlCHStSiGvWoSE2qUpfK1KY69alQjapUp8qDM5bxqh2jqgpewowBQMOrzwCrM8TaDLJ29atoDWtax7rWsrb1rGqN61h/UoK9FHMGBthMAwzgnUyO55IPGcAJBGsCwpbAsCRA7AgUKwLGAsCxkB2sZAs72cNWNrGDbYlr4hQaGVinOZTaT8pMBNh8RJayqLVsajG72sVe1rWtbexrZRvbx0pWs815DgL6spo6+WkCNiJYjyJQN5T2M5eqKa1ta3ta1TqXtc+FbXRpO93lVre5/9BlrWbB1Z+6UMtEDtAfjjT00s/2UzEOgEADNqlCdmBXutmFr3ypG1/6zte69cXvfd9rX+pqVjXBdJx5M8O2BhBOPcalFCgDczlLBoC/+u1vhCcM4QrPlsIXtvAINNskBDyJTwO+5ZMiAKNbgvZjrnmALwN5EgwzN8MwfrGMrxvj6OKWRdmTUIitY5z+mbifCSDxAw7DXhSeRMM0nnF+kbzkGje5BJq1VOb2xDwC28VEtgvxCCCQrQl4J4cfYfJ+nTxmJZc5yWhOLF21SoLAklnCYobzm12c5jMn9r9s5qpZl7FnAfT5z2/lc6D9PGhAy9Wth4YrW9WKDjajwKpYjf+0LDzm6Epb+tKYzrSmN83pTnv606AOtahHTepSmzoqkJa0qrFKaRG+xNCLjjWiZa3oWdu61rgWdKJ1TWte39rXuSb0roXda2LPutEn/Eec6fzkOsvZzM92NrPtTO1n45mTHVZWBNj2Q76SYK8IAKWWUHCX1RSZV26G9rSj3ex2V3vd8F62vG+75r5RwJmQOUsJTjwC0BovBZC0nbXCPOd5q9vg0ka4u9m932v7Mz/Oyrdo/ERNslD8cK0TjmxIUJ0LLeDeA5+Iwt89coabPN4FTzlz630mxQxZMZBZHjC3c7iZw2YxrXPPNp2pgAjU9FctLjnKD67yhBd94UMngcP/PzOBw+xoeafJC2ijXmW3HYi851FxYHi4rAcfneRfP7nQxx52/S69cM55OntODFq24/wxQWqoDe0Drmu5t+xkJ7rejb53pGP37C96jYSWVx36YRw1lhKLhKyEpSUdwAEUwBKUut6OvPP98n7Hu+b3DvgIxdxMT7Lc8EIPptYtClDcarpgIHDuXSl785gHe99lH3uxx9jhHeSqsYMN61/vHtjA/73we8/7Qht/2MQPfvIJjWwTpnrV0Bdjq09N/epb//rYz772t8/97nv/++APv/jHT/7ym//86L9Y9NfP/vYfcfpO0X1P5k//+tv//vjPv0+s0uKnOlwsQmBXP6cH/w9GWANggAjYWAn4WAt4gAr4gAwIgQ4YgRQ4gRbYgBgogRlYgRt4gRr4gRwIgh4YgiQ4gibYgSgogilYgit4gir4ggzIclRyKD3QGZ/RWYDQf061dDS4V8NRLEPyAMkxAROAFgpDOBBAGbllIAOIBzrYVDxIAhMQAQWQMPXzGTZXc5ZTIiEVU/zhH4HwhEwVhdwCG5hRHc/RHFK3GIOkTv0WYOPGB/fggiwIg3R4hy2Yh3aoh3XYh3i4h4Doh3z4h4IYiIR4iIJFhsViOQb2djoyPG2nLUJSHx32YWF4Ef4ngz/yGDKCeIcnGuZieIuhHJByABFAGHWSY2+zB2K4VJ48GBjfIRilBzykNzwP8Cj1IWU4IwitqFS4FwORd4tYFAkFyGdgdYDGmIx+dozMqIzIuIzO2IzQOI3PWI3SaI3RmI3UeI3cqI3YuI3e2I3gOI7fWI7iaI7hmI7keI7sqI7ouI2aOAPZAimT8Hzud4/4mI+6AH/p14/++I8AGZACOZAEWZAGeZAImZAKuZAM2ZAO+ZAQGZESOZEU6SshAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the pre-S/surface open reading frame (ORF), RNA transcripts and translational products. The pre-S/S ORF consists of three in-phase start codons and a common stop codon that divides the gene into pre-S1, pre-S2 and S regions encoding the large (L), middle (M), and small (S) envelope proteins, respectively. The M and S envelope proteins are found in all forms of viral and subviral particles while the L envelope proteins are predominantly found in complete virions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43580=[""].join("\n");
var outline_f42_35_43580=null;
var title_f42_35_43581="Rifampin and HAART";
var content_f42_35_43581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Coadministration of antiretroviral drugs with RIFAMPIN",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended change in dose of antiretroviral drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended change in dose of rifampin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Non-nucleoside reverse transcriptase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Efavirenz",
"       </td>",
"       <td>",
"        None (some experts recommend 800 mg for patients &gt;50 kg)",
"       </td>",
"       <td>",
"        No change (600 mg/day)",
"       </td>",
"       <td>",
"        Efavirenz AUC &darr; by 22 percent; no change in rifampin concentration. Efavrirenz should not be used during the&nbsp;first trimester of pregnancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nevirapine",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and nevirapine should not be used together*",
"       </td>",
"       <td>",
"        Nevirapine AUC &darr; 37 to 58 percent and Cmin &darr; 68 percent with 200 mg twice daily dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rilpivirine",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and rilpivirine should not be used together",
"       </td>",
"       <td>",
"        Rilpivirine AUC &darr; by 80 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etravirine",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and etravirine should not be used together",
"       </td>",
"       <td>",
"        Marked decrease in etravirine predicted, based on data on the interaction with rifabutin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Single protease inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ritonavir",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        No change (600 mg/day)",
"       </td>",
"       <td>",
"        Use with caution. Ritonavir AUC &darr; by 35 percent; no change in rifampin concentration. Monitor for antiretroviral activity of ritonavir.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        fos-Amprenavir",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and fos-amprenavir should not be used together",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atazanavir",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and atazanavir should not be used together",
"       </td>",
"       <td>",
"        Atazanavir AUC &darr; by &gt;95 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Indinavir",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and indinavir should not be used together",
"       </td>",
"       <td>",
"        Indinavir AUC &darr; by 89 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nelfinavir",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and nelfinavir should not be used together",
"       </td>",
"       <td>",
"        Nelfinavir AUC &darr; 82 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saquinavir",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and saquinavir should not be used together",
"       </td>",
"       <td>",
"        Saquinavir AUC by &darr; 84 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Dual protease-inhibitor combinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saquinavir/ritonavir",
"       </td>",
"       <td>",
"        Saquinavir 400 mg + ritonavir 400 mg twice daily",
"       </td>",
"       <td>",
"        No change (600 mg/day)",
"       </td>",
"       <td>",
"        Use with caution; the combination of saquinavir (1000 mg twice daily), ritonavir (100 mg twice daily), and rifampin caused unacceptable rates of hepatitis among healthy volunteers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lopinavir/ritonavir (Kaletra)",
"       </td>",
"       <td>",
"        Increase the dose of lopinavir/ritonavir (Kaletra)&nbsp;four tablets (200 mg of lopinavir with 50 mg of ritonavir) twice daily",
"       </td>",
"       <td>",
"        No change (600 mg/day)",
"       </td>",
"       <td>",
"        Use with caution; this combination resulted in hepatitis in all adult healthy volunteers in an initial study.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        \"Super-boosted\" lopinavir/ritonavir (Kaletra)",
"       </td>",
"       <td>",
"        Lopinavir/ritonavir (Kaletra)&nbsp;two tablets (200 mg of lopinavir with 50 mg of ritonavir) + 300 mg of ritonavir twice daily",
"       </td>",
"       <td>",
"        No change (600 mg/day)",
"       </td>",
"       <td>",
"        Use with caution; this combination resulted in hepatitis among adult healthy volunteers. However, there are favorable pharmacokinetic and clinical data among young children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atazanavir/ritonavir",
"       </td>",
"       <td colspan=\"2\">",
"        The standard dose of ritonavir-boosted atazanavir (300 mg once daily with 100 mg of ritonavir) should not be used with rifampin",
"       </td>",
"       <td>",
"        Atazanavir trough concentration by &gt;90 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tipranavir/ritonavir",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and tipranavir/ritonavir should not be used together",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Darunavir/ritonavir",
"       </td>",
"       <td colspan=\"2\">",
"        Rifampin and darunavir/ritonavir should not be used together",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        CCR-5 receptor antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maraviroc",
"       </td>",
"       <td>",
"        Increase maraviroc to 600 mg twice daily",
"       </td>",
"       <td>",
"        No change (600 mg/day)",
"       </td>",
"       <td>",
"        Coadministration is not recommended. If coadmininistration is necessary, use miraviroc 600 mg twice daily. If coadministered with a strong CYP3A inhibitor, use miraviroc 300 mg twice daily.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Integrase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raltegravir",
"       </td>",
"       <td>",
"        Dose raltegravir 800 mg twice daily. Monitor closely for virologic response.",
"       </td>",
"       <td>",
"        No change (600 mg/day)",
"       </td>",
"       <td>",
"        Raltegravir 400 mg: AUC &darr; 40 percent and Cmin &darr; 61 percent. Rifampin with raltegravir 800 mg twice daily compared with raltegravir 400 mg twice daily alone: AUC &uarr; 27 percent and Cmin &darr;&nbsp;53 percent.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     AUC: Area under curve; Cmin: Minimum concentration.",
"     <br>",
"      <br>",
"       * DHHS advises against coadministration of rifampin with nevirapine; see text for additional discussion.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Department of Health and Human Services:",
"      <a href=\"file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf\">",
"       file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf",
"      </a>",
"      (November 21, 2012).",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43581=[""].join("\n");
var outline_f42_35_43581=null;
var title_f42_35_43582="Retinal disease in SLE";
var content_f42_35_43582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal disease in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of the retina from a patient with systemic lupus erythematosus shows multiple peripapillary cotton wool spots, hemorrhage, and a central retinal artery occlusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_35_43582=[""].join("\n");
var outline_f42_35_43582=null;
var title_f42_35_43583="Molluscum contagiosum";
var content_f42_35_43583=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Molluscum contagiosum (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/35/43583/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43583/contributors\" id=\"au4272\">",
"       Stuart N Isaacs, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/35/43583/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43583/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/35/43583/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/35/43583/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/35/43583?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Molluscum contagiosum is the name of a virus that causes a common skin infection. The infection can develop in children and adults. The virus is spread by skin-to-skin contact. Symptoms of molluscum include small, flesh-colored growths on the skin.",
"    </p>",
"    <p>",
"     Molluscum contagiosum usually resolves on its own without complications after a few months. Treatment is recommended to get rid of growths in the genital area. Treatment for other areas is available but often is not necessary.",
"    </p>",
"    <p>",
"     More detailed information about molluscum is available to readers by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6842?source=see_link\">",
"      \"Molluscum contagiosum\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      MOLLUSCUM SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of molluscum include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Small, dome-shaped bumps with a dimple in the center (",
"       <a class=\"graphic graphic_picture graphicRef65763 \" href=\"mobipreview.htm?17/12/17600\">",
"        picture 1",
"       </a>",
"       ). The bumps are the size of a pin to pencil eraser (2 to 5 millimeters). Most people have a group or line of bumps together. People with a weakened immune system may develop larger bumps in large groups.",
"      </li>",
"      <li>",
"       The bumps are flesh colored to white and do not hurt or itch.",
"      </li>",
"      <li>",
"       The bumps can appear anywhere on the body except the palms of the hands and soles of the feet.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      How did I get molluscum?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The virus is spread by skin-to-skin contact. This means that you can spread the virus:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       From one area of the body to another by scratching or touching a bump",
"      </li>",
"      <li>",
"       During contact sports or sexual activity",
"      </li>",
"      <li>",
"       By sharing bath towels or washcloths",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The bumps usually appear two to six weeks after you are exposed to the virus. A healthcare provider can usually diagnose molluscum based on an exam; a biopsy is not usually necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      How do I avoid infecting other people?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have molluscum on your penis, vulva, upper inner thighs, buttocks, or skin immediately above the genitals, you should be treated so that you do not spread the virus to others during sex. If you have molluscum on other areas, you can reduce the likelihood of spread by covering the bumps during the day with clothing or a bandage.",
"    </p>",
"    <p>",
"     Do not share towels, washcloths, razors, or other personal equipment. Once the bumps have resolved, you cannot spread the virus to others. However, you can become infected again, so do not touch molluscum bumps on other people.",
"    </p>",
"    <p>",
"     If your child has molluscum and attends daycare or school, try to cover the bumps with a bandage or clothing. Children with molluscum that cannot be covered should avoid wrestling or rough-housing to reduce the risk of spread of the infection to others.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      MOLLUSCUM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     In healthy people, the skin growths caused by molluscum usually disappear without treatment within a few months. People with weakened immune systems can develop more severe infections, which take longer to resolve.",
"    </p>",
"    <p>",
"     Treatment is recommended in sexually active adolescents and adults to get rid of molluscum on the penis, vulva, skin near the genitals, or buttocks because treatment of these areas can help to prevent the spread of the infection to other people during sex.",
"    </p>",
"    <p>",
"     Treatment for molluscum in children is optional since the molluscum will eventually heal on their own. Reasons why molluscum may be treated include cosmetic concerns or to try to prevent the spread of infection to other body areas, siblings, or playmates.",
"    </p>",
"    <p>",
"     There are several treatment options for molluscum, which include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Freezing the growths (called cryotherapy)",
"      </li>",
"      <li>",
"       Scraping off the growths",
"      </li>",
"      <li>",
"       A treatment called cantharidin, which forms a blister and gets rid of the molluscum once the blister heals",
"      </li>",
"      <li>",
"       A liquid or cream, similar to those used to treat warts (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/16/25857?source=see_link\">",
"        \"Patient information: Skin warts (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     No one treatment for molluscum has proven to be the \"best.\" Therefore, treatment usually depends on where the growths are located, your preferences, and the preferences of your healthcare provider. You should try not to pick or scrape off the bumps yourself because you may cause a bacterial infection of the skin or may spread the molluscum virus to other areas.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784900564\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518555\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Basic content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518563\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/16/25857?source=see_link\">",
"      Patient information: Skin warts (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6842?source=see_link\">",
"      Molluscum contagiosum",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000826.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000826.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncidod/dvrd/molluscum/\">",
"      www.cdc.gov/ncidod/dvrd/molluscum/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?42/35/43583/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/35/43583?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43583/abstract/1\">",
"      Hanna D, Hatami A, Powell J, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatr Dermatol 2006; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/35/43583/abstract/2\">",
"      van der Wouden JC, van der Sande R, van Suijlekom-Smit LW, et al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev 2009; :CD004767.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f42_35_43583=[""].join("\n");
var outline_f42_35_43583=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           MOLLUSCUM SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           MOLLUSCUM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/12/17600\" title=\"picture 1\">",
"           Typical molluscum bumps",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
